Two-piece, internal-channel osmotic delivery system flow modulator

Information

  • Patent Grant
  • 9539200
  • Patent Number
    9,539,200
  • Date Filed
    Thursday, February 26, 2015
    9 years ago
  • Date Issued
    Tuesday, January 10, 2017
    7 years ago
Abstract
An osmotic delivery system flow modulator includes an outer shell constructed and arranged for positioning in an opening, an inner core inserted in the outer shell, and a fluid channel having a spiral shape defined between the outer shell and the inner core. The fluid channel is adapted for delivery of an active agent formulation from the reservoir of the osmotic delivery system.
Description
BACKGROUND OF THE INVENTION

The invention relates generally to osmotic delivery systems for sustained delivery of active agents in fluid environments. More particularly, the invention relates to a flow modulator for delivering an active agent from an osmotic delivery system in a fluid environment.



FIG. 1 illustrates a prior-art osmotic delivery system 40, as described in U.S. Pat. No. 6,524,305 issued to Peterson et al. The osmotic delivery system 40 includes an enclosure 42 containing osmotic agent 47 and active agent 44. A dividing member 46 forms a partition between the osmotic agent 47 and the active agent 44. A semipermeable plug 48 is inserted into a first opening 45 of the enclosure 42. The semipermeable plug 48 selectively permits fluid to enter the interior of the enclosure 42. A flow modulator 20 is inserted into a second opening 39 of the enclosure 42. The flow modulator 20 allows the active agent 44 to exit the interior of the enclosure 42 while controlling back-diffusion of fluids into the interior of the enclosure 42. When the osmotic delivery system 40 is disposed in a fluid environment, fluid from the exterior of the enclosure 42 enters the enclosure 42 through the semipermeable plug 48 and permeates the osmotic agent 47, causing the osmotic agent 47 to swell. The osmotic agent 47 displaces the dividing member 46 as it swells, causing an amount of the active agent 44 to be delivered to the environment of use through the flow modulator 20.


In the prior-art osmotic delivery system 40 shown in FIG. 1, the outer surface of the flow modulator 20 includes a helical delivery path 32 through which the active agent 44 passes from the interior to the exterior of the enclosure 42. The thread 36 which defines the helical delivery path 32 abuts the interior surface 43 of the enclosure 42 so that the active agent 44 comes into contact with the interior surface 43 of the enclosure 42 as it passes through the helical delivery path 32. The pitch, amplitude, cross-sectional area, and shape of the helical delivery path 32 are selected such that back-diffusion into the enclosure 42 from the fluid environment is minimized. Fill hole 22 and vent hole 24 are provided in the flow modulator 20. When assembling the osmotic delivery system 40, the flow modulator 20 is first inserted in the enclosure 42. The active agent 44 is then injected into the enclosure 42 through the fill hole 22, while gases in the enclosure 42 escape through the vent hole 24. Thereafter, caps 26 are inserted in the holes 22, 24 so that delivery of the active agent 44 occurs only through the helical delivery path 32.


From the foregoing, there continues to be a desire to provide additional reliability and flow modulator capabilities in osmotic delivery systems.


SUMMARY OF THE INVENTION

In one aspect, the invention relates to an osmotic delivery system flow modulator which comprises an outer shell constructed and arranged for positioning in an opening of a reservoir of an osmotic delivery system, an inner core inserted in the outer shell, and a fluid channel having a spiral shape defined between the outer shell and the inner core, the fluid channel being adapted for delivery of an active agent formulation from the reservoir of the osmotic delivery system.


In another aspect, the invention relates to an osmotic delivery system which comprises a reservoir, a semipermeable plug disposed at a first end of the reservoir to selectively permit flow into the reservoir, a flow modulator disposed at a second end of the reservoir, the flow modulator comprising an internal spiral channel adapted for delivery of an active agent formulation contained in the reservoir to a fluid environment in which the osmotic delivery system operates.


In yet another aspect, the invention relates to an implantable delivery system for an active agent formulation which comprises a reservoir made of an impermeable material, a first chamber in the reservoir containing an osmotic engine, a second chamber in the reservoir containing an active agent formulation, a semipermeable plug disposed at a first end of the reservoir adjacent the first chamber, and a flow modulator as described above disposed at a second end of the reservoir adjacent the second chamber.


Other features and advantages of the invention will be apparent from the following description and the appended claims.





BRIEF DESCRIPTION OF THE DRAWINGS

The accompanying drawings, described below, illustrate typical embodiments of the invention and are not to be considered limiting of the scope of the invention, for the invention may admit to other equally effective embodiments. The figures are not necessarily to scale, and certain features and certain view of the figures may be shown exaggerated in scale or in schematic in the interest of clarity and conciseness.



FIG. 1 depicts a cross-sectional view of a prior-art osmotic delivery system.



FIG. 2A depicts a partial cross-sectional view of a flow modulator having an inner core inserted in an outer shell and an internal spiral fluid channel formed in the inner core.



FIG. 2B depicts a partial cross-sectional view of a flow modulator having an inner core inserted in an outer shell and an internal spiral fluid channel formed in the outer shell.



FIG. 2C depicts a partial cross-sectional view of a flow modulator having an inner core inserted in an outer shell and an internal spiral fluid channel formed in the inner core and the outer shell.



FIG. 2D depicts a partial cross-sectional view of a flow modulator having an inner core inserted in an outer shell and a flow insert including an internal spiral fluid channel interposed between the inner core and the outer shell.



FIG. 2E depicts a partial cross-section view of a flow modulator having an inner core inserted in an outer shell and mating surfaces on the inner core and outer shell for preventing expulsion of the inner core from the outer shell.



FIG. 3 depicts a cross-sectional view of an osmotic delivery system with the flow modulator of FIG. 2A.



FIG. 4 depicts an in vitro cumulative release of an active agent using an osmotic delivery system according to FIG. 3.





DETAILED DESCRIPTION OF THE INVENTION

The invention will now be described in detail with reference to a few preferred embodiments, as illustrated in the accompanying drawings. In describing the preferred embodiments, numerous specific details are set forth in order to provide a thorough understanding of the invention. However, it will be apparent to one skilled in the art that the invention may be practiced without some or all of these specific details. In other instances, well-known features and/or process steps have not been described in detail so as not to unnecessarily obscure the invention. In addition, like or identical reference numerals are used to identify common or similar elements.



FIGS. 2A through 2E depict partial cross-sectional views of a flow modulator 200 for delivery of an active agent formulation from a reservoir of an osmotic delivery system. Referring to FIG. 2A, the flow modulator 200 has an inlet side 201, which is the side that would be exposed to the active agent formulation in the reservoir of the osmotic delivery system, and an outlet side 203, which is the side that would be exposed to a fluid environment in which the osmotic delivery system operates. Typically, the fluid environment is an aqueous environment, that is, the fluid environment contains water. The flow modulator 200 includes an outer shell 202 and a generally cylindrical inner core 204 inserted in the outer shell 202. Extending from the inlet side 201 to the outlet side 203 of the flow modulator 200, between the outer shell 202 and the inner core 204, is a fluid channel 206 having a spiral shape. All or a substantial portion of the fluid channel 206 may have a spiral shape. The fluid channel 206 is internal to the flow modulator 200. The flow modulator 200 therefore forms a barrier between active agent formulation passing through the fluid channel 206 and the reservoir of the osmotic delivery system.


In FIGS. 2A-2C, the outer surface 210 of the inner core 204 mates with the inner surface 212 of the outer shell 202. The fluid channel 206 may be formed in the outer surface 210 of the inner core 204, as shown in FIG. 2A, or in the inner surface 212 of the outer shell 202, as shown in FIG. 2B. Alternatively, as shown in FIG. 2C, the fluid channel 206 may include a first fluid channel 206a formed in the outer surface 210 of the inner core 204 and a second fluid channel 206b formed in the inner surface 212 of the outer shell 202, wherein the first fluid channel 206a and the second fluid channel 206b are adjacent to each other or in communication. All or a substantial portion of each of the fluid channels 206a, 206b has a spiral shape. Alternatively, as shown in FIG. 2D, a flow insert 214 may be disposed between the outer surface 210 of the inner core 204 and the inner surface 212 of the outer shell 202, wherein the flow insert 214 provides the fluid channel 206. The flow insert 214 may be a coiled tube, for example, wherein the spaces between the coils of the tube serve as the fluid channel 206. Alternatively, the flow insert 214 may be a hollow cylindrical body or a sleeve in which a spiral groove is formed, where the spiral groove serves as the fluid channel 206. The fluid channel 206 may have any desired cross-section, examples of which include circular or D shape. D-shaped fluid channels are shown in FIGS. 2A-2E. The length of the fluid channel 206 depends on the configuration of the osmotic delivery system and the desired release rate. Typically, the (spiral) length of the fluid channel 206 ranges from 10 to 50 mm. Typically, the effective cross-sectional diameter of the fluid channel 206 ranges from 0.1 to 0.5 mm. These ranges are given as examples and are not intended to limit the invention as otherwise described herein.


Referring to FIGS. 2A-2D, the largest outer diameter of the inner core 204 and the largest inner diameter of the outer shell 202 are selected such that there is an interference fit or a seal between the outer surface 210 of the inner core 204 and the inner surface 212 of the outer shell 202. This interference fit or seal confines the flow of formulation to the fluid channel 206. This interference fit or seal may be sufficient to prevent expulsion of the inner core 204 and/or flow insert 214 from the outer shell 202. On the other hand, in FIGS. 2A-2C, the mating portion of the surfaces 210, 212 of the inner core 204 and outer shell 202, respectively, may include features such as threaded connection, bonded connection, welded connection, and the like to additionally secure the inner core 204 to the outer shell 202. In FIG. 2D, similar connection features may be formed between the portions of the inner and outer surfaces 214a, 214b of the flow insert 214 which mate with the surfaces 210, 212 of the inner core 204 and outer shell 202, respectively. FIG. 2E discloses an alternate method for preventing expulsion of the inner core 204 from the outer shell 202 which includes an outer shoulder 216 on the outer surface 210 of the inner core 204 abutting/engaging an inner shoulder 218 on the inner surface 212 of the outer shell 202. This prevents expulsion of the inner core 204 through the outlet side 203 of the flow modulator 200. The abutting/engaging surfaces of the shoulders 216, 218 may be flat or may be tapered, as shown in FIG. 2E.


The use of abutting/engaging shoulders 216, 218 to prevent expulsion of the inner core 204 from the outer shell 202 into the fluid environment in which the osmotic delivery system operates may be applied to any of the examples shown in FIGS. 2A-2D. Further, any of the features of the examples shown in FIGS. 2A-2E may be interchanged and combined to make alternate examples of the flow modulator 200. For example, in FIG. 2E, a channel having a spiral shape may also be located in the inner surface 212 of the outer shell 202, as described in FIG. 2C. Or, in FIG. 2D, channels having a spiral shape may also be located in the inner surface 212 of the outer shell 202 and/or outer surface 210 of the inner core 204, as described in FIGS. 2A and 2B, respectively, where the channels in the outer shell 202 and/or inner core 204 would be adjacent to or in communication with the fluid channel 206 in the flow insert 214.


Referring to FIGS. 2A-2E, the outer shell 202, the inner core 204, and the flow insert 214 are preferably formed from a material that is inert and biocompatible. Examples of inert, biocompatible materials include, but are not limited to, non-reactive polymers and metals such as titanium, stainless steel, platinum and their alloys, and cobalt-chromium alloys. Non-reactive polymers are useful where it is desirable to avoid interaction between the active agent formulation and a metallic material as the active agent formulation is delivered to the fluid environment in which the osmotic delivery system operates. Examples of suitable non-reactive polymers include, but are not limited to, polyaryletherketones, such as polyetheretherketone and polyaryletheretherketone, ultra-high molecular weight polyethylene, fluorinated ethylene-propylene, polymethylpentene, and liquid crystal polymers. Preferably, at least the surfaces of the outer shell 202, the inner core 204, and the flow insert 214 which would be exposed to the active agent formulation as the active agent formulation flows through the fluid channel 206 are made of or coated with a material that would not have a detrimental effect on the active agent formulation. In a preferred example, the aforementioned surfaces are made of a non-metallic material that is inert and biocompatible. Such non-metallic material could be a non-reactive polymer, examples of which are given above.


The length, the cross-sectional shape, and flow area of the fluid channel 206 may be selected such that the average linear velocity of the active agent formulation through the fluid channel 206 is higher than that of the linear inward influx of materials due to diffusion or osmosis from the fluid environment in which the osmotic delivery system operates. This would have the effect of attenuating or moderating back diffusion, which if not controlled could contaminate the active agent formulation in the osmotic delivery system. The release rate of the active agent formulation can be modified by modifying the geometry of the fluid channel 206, as described below.


The convective flow of an active agent through the fluid channel 206 is determined by the pumping rate of the osmotic delivery system and the concentration of the active agent in the active agent formulation in the reservoir of the osmotic delivery system. The convective flow may be expressed as follows:

Qca=(Q)(Ca)  (1)

where Qca is the convective transport of beneficial in mg/day, Q is the overall convective transport of the active agent formulation in cm3/day, and Ca is the concentration of active agent in the active agent formulation within the reservoir of the osmotic delivery system in mg/cm3.


The diffusive flow of active agent out of the fluid channel 206 is a function of active agent concentration and diffusivity and cross-sectional shape and length of the fluid channel 206. The diffusive flow may be expressed as follows:










Q
da

=


D





π






r
2


Δ






C
a


L





(
2
)








where Qda is the diffusive transport of the active agent in mg/day, D is the diffusivity through the fluid channel 206 in cm2/day, r is the effective inner radius of the fluid channel 206 in cm, ΔCa is the difference between the concentration of the active agent in the active agent formulation in the reservoir of the osmotic delivery system and the concentration of the active agent in the fluid environment outside of the delivery orifice 205 of the flow modulator 200 in mg/cm3, and L is the (spiral) length of the fluid channel 206 in cm.


In general, the concentration of active agent in the active agent formulation in the osmotic delivery system is much greater than the concentration of the active agent in the fluid environment of use such that the difference, ΔCa can be approximated by the concentration of the active agent within the active agent formulation in the osmotic delivery system, Ca. Thus:










Q
da

=


D





π






r
2


Δ






C
a


L





(
3
)







It is generally desirable to keep diffusive flux of the active agent much less than convective flow of the active agent. This is represented as follows:











Q
da


Q
ca


=



D





π






r
2



C
a




QC
a


L


=



D





π






r
2


QL

<
1






(
4
)








Equation (4) indicates that the relative diffusive flux decreases with increasing volumetric flow rate and path length, increases with increasing diffusivity and channel radius, and is independent of active agent concentration.


The diffusive flux of water where the fluid channel 206 opens into the osmotic delivery system can be approximated as follows:

Qwd(res)=C0Qe(−QL/DwA)  (5)

where Co is the concentration profile of water in mg/cm3, Q is the mass flow rate in mg/day, L is the length of the fluid channel 206 in cm, Dw is the diffusivity of water through the material in the fluid channel 206 in cm2/day, and A is the cross-sectional area of the fluid channel 206 in cm2.


The hydrodynamic pressure drop across the delivery orifice can be calculated as follows:










Δ





P

=


8





QL





μ


π






r
4







(
6
)








where Q is the mass flow rate in mg/day, L is the length of the spiral fluid channel in cm, μ is the viscosity of the formulation, and r is the effective inner radius of the fluid channel in cm.



FIG. 3 shows an osmotic delivery system 300 including the flow modulator 200. Although the osmotic delivery system 300 is shown with the flow modulator 200 of FIG. 2A, it should be clear that any of the flow modulators 200 shown in FIGS. 2A-2E may be used with the osmotic delivery system 300. The osmotic delivery system 300 includes a reservoir 302, which may be sized such that it can be implanted within a body. The reservoir 302 has open ends 304, 306. The flow modulator 200 is inserted in the open end 304. A semipermeable plug 308 is inserted in the open end 306.


The semipermeable plug 308 is a membrane that controls rate of flow of fluid from the fluid environment in which the osmotic delivery system operates into the reservoir 302. The semipermeable plug 308 allows fluid from the fluid environment to enter the reservoir 302. Compositions in the reservoir 302 are prevented from flowing out of the reservoir 302 through the semipermeable plug 308 because of the semipermeable nature of the semipermeable plug 308. The semipermeable plug 308 may be inserted partially or fully into the open end 306. In the former case, the semipermeable plug 308 may include an enlarged end portion 308a which acts as a stop member engaging an end of the reservoir 302. The outer surface 308b of the semipermeable plug 308 may have protrusions or ribs 308c that engage the inner surface 310 of the reservoir 302, thereby locking the semipermeable plug 308 to the reservoir 302 and allowing a seal to be formed between the reservoir 302 and the semipermeable plug 308. The reservoir 302 may also include undercuts which receive the protrusions 308c on the semipermeable plug 308. Semipermeable materials for the semipermeable plug 308 are those that can conform to the shape of the reservoir 302 upon wetting and that can adhere to the inner surface 310 of the reservoir 302. Typically, these materials are polymeric materials, which can be selected based on the pumping rates and system configuration requirements. Examples of suitable semipermeable materials include, but are not limited to, plasticized cellulosic materials, enhanced polymethyl methacrylates (PMMAs) such as hydroxyethylmethacrylate (HEMA), and elastomeric materials, such as polyurethanes and polyamides, polyether-polyamind copolymers, thermoplastic copolyesters, and the like. Polyurethanes are generally preferred.


Two chambers 312, 314 are defined inside the reservoir 302. The chambers 312, 314 are separated by a partition 316, such as a slidable piston or flexible diaphragm, which is configured to fit within and make sealing contact with the reservoir 302 and to move or deform longitudinally within the reservoir 302. Preferably, the partition 316 is formed of an impermeable resilient material. As an example, the partition 316 may be a slidable piston made of an impermeable resilient material and may include annular ring shape protrusions 316a that form a seal with the inner surface 310 of the reservoir 302. Osmotic engine 318 is disposed in the chamber 314 adjacent the semipermeable plug 308, and an active agent formulation 320 is disposed in the chamber 312 adjacent the flow modulator 200. The partition 316 isolates the active agent formulation 320 from the environmental fluids that are permitted to enter the reservoir 302 through the semipermeable plug 308 such that in use, at steady-state flow, the active agent formulation 320 is expelled through the fluid channel 206 at a rate corresponding to the rate at which fluid from the fluid environment flows into reservoir 302 through the semipermeable plug 308.


The osmotic engine 318 may be in the form of tablets as shown. One or more such tablets may be used. Alternatively, the osmotic engine 318 may have other shape, texture, density, and consistency. For example, the osmotic engine 318 may be in powder or granular form. The osmotic engine 318 may include an osmopolymer. Osmopolymers are hydrophilic polymers that can imbibe aqueous fluids, such as water and biological fluids, and upon imbibing aqueous fluids swell or expand to an equilibrium state and retain a significant portion of the imbibed fluid. Osmopolymers swell or expand to a very high degree, usually exhibiting 2 to 50 fold volume increase. Osmopolymers may or may not be cross-linked. Preferred osmopolymers are hydrophilic polymers that are lightly cross-linked, such cross-links being formed by covalent or ionic bonds or residue crystalline regions after swelling. Osmopolymers can be of plant, animal or synthetic origin. Examples of osmopolymers or hydrophilic polymers suitable for use in the osmotic engine 318 include, but are not limited to, poly (hydroxy-alkyl methacrylate) having a molecular weight of from 30,000 to 5,000,000; polyvinylpyrrolidone (PVP) having a molecular weight of from 10,000 to 360,000; anionic and cationic hydrogels; polyelectrolytes complexes; polyvinyl alcohol having a low acetate residual, cross-linked with glyoxal, formaldehyde, or glutaraldehyde and having a degree of polymerization of from 200 to 30,000, a mixture of methyl cellulose, cross-linked agar and carboxymethyl cellulose; a mixture of hydroxypropyl methylcellulose and sodium carboxymethylcellulose; a mixture of hydroxypropyl ethylcellulose and sodium carboxymethyl cellulose; sodium carboxymethylcellulose; potassium carboxymethylcellulose; a water insoluble, water swellable copolymer formed from a dispersion of finely divided copolymer of maleic anhydride with styrene, ethylene, propylene, butylene or isobutylene cross-linked with from 0.001 to about 0.5 moles of saturated cross-linking agent per mole of maleic anhydride per copolymer; water swellable polymers of N-vinyl lactams; polyoxyethylene-polyoxypropylene gel; polyoxybutylene-polyethylene block copolymer gel; carob gum; polyacrylic gel; polyester gel; polyuria gel; polyether gel; polyamide gel; polycellulosic gel; polygum gel; and initially dry hydrogels that imbibe and absorb water which penetrates the glassy hydrogel and lowers its glass temperature. Other examples of osmopolymers include polymers that form hydrogels, such as CARBOPOL®, acidic carboxypolymer, a polymer of acrylic and cross-linked with a polyallyl sucrose, also known as carboxypolymethylene and carboxyvinyl polymer having a molecular weight of 250,000 to 4,000,000; CYNAMER® polyacrylamides; cross-linked water swellable indene-maleic anhydride polymers; GOOD-RITE® polyacrylic acid having a molecular weight of 80,000 to 200,000; POLYOX® polyethylene oxide polymer having a molecular weight of 100,000 to 5,000,000 and higher; starch graft copolymers; AQUA-KEEPS® acrylate polymer polysaccharides composed of condensed glucose units such as diester cross-linked polygluran; and the like. The osmotic engine 318 may also include an osmagent either in addition to or in lieu of the osmopolymer. Osmagents include inorganic and organic compounds that exhibit an osmotic pressure gradient across a semipermeable wall against an external fluid. Osmagents imbibe fluid into the osmotic system, thereby making available fluid to push against the formulation for delivery through the flow modulator. Osmagents are also known as osmotically effective compounds or solutes. Osmagents useful in the osmotic engine 318 include magnesium sulfate, magnesium chloride, sodium chloride, potassium sulfate, sodium sulfate, lithium sulfate, potassium acid phosphate, mannitol, urea, inositol, magnesium succinate, tartaric acid, carbohydrates such as raffinose, sucrose, glucose, lactose, sorbitol, and mixtures thereof.


The active agent formulation 320 may include one or more active agents. The active agent may be any physiologically or pharmacologically active substance, particularly those known to be delivered to the body of a human or an animal, such as medicaments, vitamins, nutrients, or the like. Active agents which may be delivered by the osmotic delivery system 300 through the flow modulator 200 include, but are not limited to, drugs that act on infectious diseases, chronic pain, diabetes, the peripheral nerves, adrenergic receptors, cholinergic receptors, the skeletal muscles, the cardiovascular system, smooth muscles, the blood circulatory system, synoptic sites, neuroeffector junctional sites, endocrine and hormone systems, the immunological system, the reproductive system, the skeletal system, autacoid systems, the alimentary and excretory systems, the histamine system and the central nervous system. Suitable agents may be selected from, for example, proteins, enzymes, hormones, polynucleotides, nucleoproteins, polysaccharides, glycoproteins, lipoproteins, polypeptides, steroids, analgesics, local anesthetics, antibiotic agents, anti-inflammatory corticosteroids, ocular drugs and synthetic analogs of these species. Preferred active agents include macromolecules (proteins and peptides) and active agents that are highly potent. The active agent can be present in a wide variety of chemical and physical forms, such as solids, liquids and slurries. In addition to the one or more active agents, the formulation 320 may optionally include pharmaceutically acceptable carriers and/or additional ingredients such as antioxidants, stabilizing agents, buffers, and permeation enhancers.


Materials that are used for the reservoir 302 should be sufficiently rigid to withstand expansion of the osmotic engine 318 without changing its size or shape. Further, the materials should ensure that the reservoir 302 will not leak, crack, break, or distort under stress to which it could be subjected during implantation or under stresses due to the pressures generated during operation. The reservoir 302 may be formed of inert, biocompatible, natural or synthetic materials which are known in the art. The material of the reservoir 302 may or may not bioerodible. A material that is bioerodible will at least in part dissolve, degrade, or otherwise erode in the fluid environment of use. Preferably, the material of the reservoir 302 is non-bioerodible. Generally, preferred materials for the reservoir 302 are those acceptable for human implantation. Preferably, the material of the reservoir 302 is impermeable, particularly when stability of the formulation in the reservoir 302 is sensitive to the fluid environment of use. Examples of materials suitable for the reservoir 302 include non-reactive polymers or biocompatible metals or alloys. Examples of non-reactive polymers for the reservoir 302 include, but are not limited to, acrylonitrile polymers such as acrylonitrile-butadiene-styrene terpolymer; halogenated polymers such as polytetraflouroethylene, polychlorotrifluoroethylene, copolymer tetrafluoroethylene and hexafluoropropylene; polyimide; polysulfone; polycarbonate; polyethylene; polypropylene; polyvinylchloride-acrylic copolymer; polycarbonate-acrylonitrile-butadiene-styrene; and polystyrene. Examples of metallic materials for the reservoir 302 include, but are not limited to, stainless steel, titanium, platinum, tantalum, gold, and their alloys, as well as gold-plated ferrous alloys, platinum-plated ferrous alloys, cobalt-chromium alloys and titanium nitride coated stainless steel. For size-critical applications, high payload capability, long duration applications, and applications where the formulation is sensitive to body chemistry at the implantation site, the reservoir 302 is preferably made of titanium or a titanium alloy having greater than 60%, often greater than 85% titanium.


The diameter of the flow modulator 200 may be selected such that the flow modulator 200 can be press-fitted into the open end 304 of the reservoir 302. It is also possible to include features such as threads on the outer surface 220 of the outer shell 202 and the inner surface 310 of the reservoir 302 for securing the flow modulator 200 to the reservoir 302.


The following examples are illustrative of the invention and are not to be construed as limiting the invention as otherwise described herein.


An osmotic delivery system, as illustrated in FIG. 3, containing interferon-omega (IFN-ω) for the treatment of, for example, hepatitis C was assembled from the following components: (i) reservoir made of implant grade titanium alloy and having undercuts at an end thereof, (ii) osmotic engine including two cylindrical tablets, each tablet including primarily sodium chloride salt with cellulosic and povidone binders, (iii) piston, (iv) semipermeable plug made of polyurethane and having retaining ribs that mate with undercuts in reservoir, (v) flow modulator having a spiral internal flow channel with a D-shaped cross-section, a diameter of 0.25 mm, and a spiral length of 35 mm, and (vi) a suspension formulation including a particle formulation of IFN-ω suspended in a non-aqueous vehicle.


Reservoirs of several osmotic delivery systems, as described above, were filled with 150-μL of the suspension formulation. The semipermeable plug ends of the osmotic delivery systems were placed into glass vials filled with phosphate buffer solution (PBS), and the flow modulator ends of the osmotic delivery systems were placed into glass vials filled with an aqueous release media. The systems were stored or incubated at 5° C. or 30° C., respectively. At specified time points, the release media was removed and exchanged for fresh solution. The sampled release media was analyzed for active agent content using Reversed Phase High Performance Liquid Chromatography (RP-HPLC). FIG. 4 shows in vitro cumulative release of IFN-ω over 6 months.


The invention may provide the following advantages. The two-piece flow modulator enables flexibility in design and manufacturability of the flow modulator. The outer shell is not integral with the reservoir and enables the channel in the flow modulator to be inspected prior to insertion of the flow modulator in the reservoir. The two-piece flow modulator minimizes additional mechanical forces on the channel during insertion of the flow modulator in the reservoir. The two-piece flow modulator enables flexibility to optimize the dimensions of the fluid channel by changing the channel on the inner core or flow insert while maintaining a common outer sleeve.


While the invention has been described with respect to a limited number of embodiments, those skilled in the art, having benefit of this disclosure, will appreciate that other embodiments can be devised which do not depart from the scope of the invention as disclosed herein. Accordingly, the scope of the invention should be limited only by the attached claims.

Claims
  • 1. A process of making a flow modulator for an osmotic delivery system, comprising: forming an outer shell member and an inner core member from at least one non-metallic, nonreactive polymer material, the outer shell member comprising an inlet end, an outlet end, and an inner surface defining an internal volume for receiving the inner core member, the inner core member comprising an outer surface for engaging with the inner surface of the outer shell member when the inner core member is disposed in the internal volume, wherein at least one groove is formed in at least one of: the inner surface of the outer shell member such that the at least one groove extends from the inlet end to the outlet end and at least a portion of the at least one groove has a helical shape around an axis from the inlet end to the outlet end; andthe outer surface of the inner core member such that when the inner core member is disposed in the internal volume, the at least one groove extends from the inlet end to the outlet end and at least a portion of the at least one groove has a helical shape around the axis from the inlet end to the outlet end; anddisposing the inner core member in the internal volume such that the outer surface of the inner core member sealingly engages the inner surface of the outer shell member and the at least one groove defines at least one fluid channel between the inner surface of the outer shell member and the outer surface of the inner core member such that the at least one fluid channel extends from the inlet end to the outlet end and at least a portion of the at least one fluid channel has a helical shape around the axis from the inlet end to the outlet end.
  • 2. The method of claim 1, wherein at least one first groove is formed in the inner surface of the outer shell member and at least one second groove is formed in the outer surface of the inner core member such that when the inner core member is disposed in the internal volume, the at least one first groove complements the at least one second groove.
  • 3. The method of claim 1, at least one non-metallic, nonreactive polymer material is at least one of a polyaryletherketone, an ultra-high molecular weight polyethylene, a fluorinated ethylene-propylene, a polymethylpentene, and a liquid crystal polymer.
  • 4. The method of claim 3, wherein the polyaryletherketone is at least one of polyetheretherketone and polyaryletheretherketone.
  • 5. The method of claim 1, wherein: the inner core member further comprises an outer shoulder;the outer shell member further comprises an inner shoulder; anddisposing the inner core member in the internal volume comprises engaging the outer shoulder and the inner shoulder to prevent expulsion of the inner core member from the outer shell member.
  • 6. The method of claim 1, wherein the at least one groove is formed only in the inner surface of the outer shell member such that when the inner core member is disposed in the internal volume, the at least one groove extends from the inlet end to the outlet end and at least a portion of the at least one groove has a helical shape around the axis from the inlet end to the outlet end.
  • 7. The method of claim 1, wherein the at least one groove is formed only in the outer surface of the inner core member such that when the inner core member is disposed in the internal volume, the at least one groove extends from the inlet end to the outlet end and at least a portion of the at least one groove has a helical shape around the axis from the inlet end to the outlet end.
  • 8. The method of claim 1, wherein the at least one groove is formed only in the outer surface of the inner core member such that when the inner core member is disposed in the internal volume, the at least one groove extends from the inlet end to the outlet end and at least a portion of the at least one groove has a helical shape around the axis from the inlet end to the outlet end.
  • 9. A method for mitigating back diffusion in an osmotic delivery system for an active agent formulation, the osmotic delivery system including a reservoir, a slidable piston defining within the reservoir a first chamber containing an osmotic engine and a second chamber containing the active agent formulation, and a semipermeable plug disposed at a first end of the reservoir adjacent the first chamber, the method comprising: providing an outer shell member and an inner core member, the outer shell member comprising an inlet end, an outlet end, and an inner surface defining an internal volume for receiving the inner core member, the inner core member comprising an outer surface for engaging with the inner surface of the outer shell member when the inner core member is disposed in the internal volume, wherein at least one groove is formed in at least one of: the inner surface of the outer shell member such that the at least one groove extends from the inlet end to the outlet end and at least a portion of the at least one groove has a helical shape around an axis from the inlet end to the outlet end; andthe outer surface of the inner core member such that when the inner core member is disposed in the internal volume, the at least one groove extends from the inlet end to the outlet end and at least a portion of the at least one groove has a helical shape around the axis from the inlet end to the outlet end;assembling a flow modulator by disposing the inner core member in the internal volume such that the outer surface of the inner core member sealingly engages the inner surface of the outer shell member and the at least one groove defines at least one fluid channel between the inner surface of the outer shell member and the outer surface of the inner core member such that the at least one fluid channel extends from the inlet end to the outlet end and at least a portion of the at least one fluid channel has a helical shape around the axis from the inlet end to the outlet end; andpositioning the flow modulator in an opening at a second end of the reservoir adjacent the active agent formulation in the osmotic delivery system such that by disposing the osmotic delivery system in a fluid environment, an amount of the active agent formulation is delivered to the fluid environment through the at least one fluid channel, the at least one fluid channel mitigating any back diffusion.
  • 10. The method of claim 9, wherein at least one first groove is formed in the inner surface of the outer shell member and at least one second groove is formed in the outer surface of the inner core member such that when the inner core member is disposed in the internal volume, the at least one first groove complements the at least one second groove.
  • 11. The method of claim 9, wherein the flow modulator is at least one of press-fitted into the opening at the second end of the reservoir and secured to the second end of the reservoir with one or more threads.
  • 12. The method of claim 9, wherein the at least one groove is formed only in the inner surface of the outer shell member such that when the inner core member is disposed in the internal volume, the at least one groove extends from the inlet end to the outlet end and at least a portion of the at least one groove has a helical shape around the axis from the inlet end to the outlet end.
  • 13. A method for regulating a release rate of an active agent formulation from an osmotic delivery system, the osmotic delivery system including a reservoir, a slidable piston defining within the reservoir a first chamber containing an osmotic engine and a second chamber containing the active agent formulation, a semipermeable plug disposed at a first end of the reservoir adjacent the first chamber, and an outer shell member disposed at a second end of the reservoir adjacent the active agent formulation, the outer shell comprising an inlet end, an outlet end, and an inner surface defining an internal volume for receiving an inner core member, the method comprising: providing one or more inner core members, each inner core member comprising an outer surface for engaging the inner surface of the outer shell member when the inner core member is disposed in the internal volume, wherein at least one groove is formed in the outer surface of each inner core member such that when the inner core member is disposed in the internal volume, the at least one groove extends from the inlet end to the outlet end and at least a portion of the at least one groove has a helical shape around the axis from the inlet end to the outlet end;selecting one of the one or more inner core members based on a geometry of the at least one groove; andassembling a flow modulator by disposing the selected inner core member in the internal volume such that the outer surface of the selected inner core member sealingly engages the inner surface of the outer shell member and the at least one groove defines at least one fluid channel between the inner surface of the outer shell member and the outer surface of the selected inner core member such that the at least one fluid channel extends from the inlet end to the outlet end and at least a portion of the at least one fluid channel has a helical shape around the axis from the inlet end to the outlet end, such that by disposing the osmotic delivery system in a fluid environment, the active agent formulation is delivered to the fluid environment through the at least one fluid channel at a release rate based at least in part on the geometry of the at least one groove.
  • 14. The method of claim 13, wherein the active agent comprises a protein or a peptide.
  • 15. The method of claim 13, wherein the geometry of the at least one groove includes a path length, an effective cross-sectional diameter of the at least one fluid channel defined by the at least one groove, and a cross-sectional shape of the at least one fluid channel defined by the at least one groove.
  • 16. The method of claim 15, wherein the path length ranges from about 10 mm to about 50 mm.
  • 17. The method of claim 16, wherein the path length is about 35 mm.
  • 18. The method of claim 15, wherein the effective cross-sectional diameter ranges from about 0.1 mm to about 0.5 mm.
  • 19. The method of claim 18, wherein the effective cross-sectional diameter is about 0.25 mm.
  • 20. The method of claim 15, wherein the cross-sectional shape is at least one of a circular shape and a D-shape.
  • 21. The method of claim 13, wherein the one or more inner core members comprise a plurality of inner core members, and the geometry of the at least one groove differs between each of the plurality of inner core members.
  • 22. The method of claim 13, further comprising: disengaging the outer surface of a first inner core member from the inner surface of the outer shell member; andremoving the first inner core member from the internal volume of the outer shell member to replace the first inner core member with the selected inner core member.
  • 23. The method of claim 22, wherein the geometry of the at least one groove in the outer surface of the selected inner core member differs from the geometry of the at least one groove in the outer surface of the first inner core member.
  • 24. The method of claim 13, wherein: the outer shell member further comprises an inner shoulder;each inner core member further comprises an outer shoulder; anddisposing the selected inner core member in the internal volume comprises engaging the outer shoulder and the inner shoulder to prevent expulsion of the selected inner core member from the outer shell member.
CROSS-REFERENCE TO RELATED APPLICATIONS

The present application claims a priority benefit as a continuation (CON) of U.S. non-provisional patent application Ser. No. 13/898,358, entitled “Two-Piece, Internal-Channel Osmotic Delivery System Flow Modulator,” filed on May 20, 2013, and issued as U.S. Pat. No. 8,992,962 on Mar. 31, 2015, the content of which is incorporated herein by reference in its entirety. U.S. non-provisional application Ser. No. 13/898,358 claims a priority benefit as a continuation (CON) of U.S. non-provisional patent application Ser. No. 13/740,187, entitled “Two-Piece, Internal-Channel Osmotic Delivery System Flow Modulator,” filed on Jan. 12, 2013, and issued as U.S. Pat. No. 8,470,353 on Jun. 25, 2013, the content of which is incorporated herein by reference in its entirety. U.S. non-provisional application Ser. No. 13/740,187 claims a priority benefit as a continuation (CON) of U.S. non-provisional patent application Ser. No. 13/601,939, entitled “Two-Piece, Internal-Channel Osmotic Delivery System Flow Modulator,” filed on Aug. 31, 2012, and issued as U.S. Pat. No. 8,367,095 on Feb. 5, 2013, the content of which is incorporated herein by reference in its entirety. U.S. non-provisional application Ser. No. 13/601,939 claims a priority benefit as a continuation (CON) of U.S. non-provisional patent application Ser. No. 13/433,287, entitled “Two-Piece, Internal-Channel Osmotic Delivery System Flow Modulator,” filed on Mar. 29, 2012, and issued as U.S. Pat. No. 8,273,365 on Sep. 25, 2012, the content of which is incorporated herein by reference in its entirety. U.S. non-provisional application Ser. No. 13/433,287 claims a priority benefit as a continuation (CON) of U.S. non-provisional patent application Ser. No. 13/209,328, entitled “Two-Piece, Internal-Channel Osmotic Delivery System Flow Modulator,” filed on Aug. 12, 2011, and issued as U.S. Pat. No. 8,158,150 on Apr. 17, 2012, the content of which is incorporated herein by reference in its entirety. U.S. non-provisional application Ser. No. 13/209,328 claims a priority benefit as a division (DIV) of U.S. non-provisional patent application Ser. No. 11/755,494, entitled “Two-Piece, Internal-Channel Osmotic Delivery System Flow Modulator,” filed on May 30, 2007, and issued as U.S. Pat. No. 8,052,996 on Nov. 8, 2011, the content of which is incorporated herein by reference in its entirety. U.S. non-provisional application Ser. No. 11/755,494 claims a priority benefit from U.S. provisional application Ser. No. 60/809,451, entitled “Two-Piece, Internal-Channel Osmotic Delivery System Flow Modulator,” filed on May 30, 2006, the content of which is incorporated herein by reference in its entirety. U.S. non-provisional application Ser. No. 11/755,494 also claims a priority benefit as a continuation-in-part (CIP) of U.S. non-provisional patent application Ser. No. 11/347,562, entitled “Solvent/Polymer Solutions as Suspension Vehicles,” filed on Feb. 3, 2006, and issued as U.S. Pat. No. 8,114,437 on Feb. 14, 2012, the content of which is incorporated herein by reference in its entirety. U.S. non-provisional application Ser. No. 11/347,562 claims a priority benefit from U.S. provisional application Ser. No. 60/650,225, entitled “Solvent/Polymer Solutions as Suspension Vehicles,” filed on Feb. 3, 2005, the content of which is incorporated herein by reference in its entirety.

US Referenced Citations (578)
Number Name Date Kind
2110208 Eggert Mar 1938 A
2168437 Buercklin Aug 1939 A
3025991 Gillon Mar 1962 A
3122162 Sands Feb 1964 A
3625214 Higuchi Dec 1971 A
3632768 Bergy et al. Jan 1972 A
3732865 Higuchi et al. May 1973 A
3797492 Place Mar 1974 A
3869549 Geller Mar 1975 A
3987790 Eckenhoff et al. Oct 1976 A
3995631 Higuchi et al. Dec 1976 A
3995632 Nakano et al. Dec 1976 A
4008719 Theeuwes et al. Feb 1977 A
4034756 Higuchi et al. Jul 1977 A
4078060 Benson et al. Mar 1978 A
4111201 Theeuwes Sep 1978 A
4111202 Theeuwes Sep 1978 A
4211771 Witkowski et al. Jul 1980 A
4243030 Lynch et al. Jan 1981 A
4305927 Theeuwes et al. Dec 1981 A
4310516 Chang et al. Jan 1982 A
4340054 Michaels Jul 1982 A
4350271 Eckenhoff Sep 1982 A
4373527 Fischell Feb 1983 A
4376118 Daher et al. Mar 1983 A
4439196 Higuchi Mar 1984 A
4455143 Theeuwes et al. Jun 1984 A
4455145 Theeuwes Jun 1984 A
4552561 Eckenhoff et al. Nov 1985 A
4588614 Lauchenauer May 1986 A
4594108 Greminger, Jr. et al. Jun 1986 A
4609374 Ayer Sep 1986 A
4639244 Rizk et al. Jan 1987 A
4655462 Balsells Apr 1987 A
4673405 Guittard et al. Jun 1987 A
4675184 Hasegawa et al. Jun 1987 A
4695623 Stabinsky Sep 1987 A
4727138 Goeddel et al. Feb 1988 A
4734284 Terada et al. Mar 1988 A
4743449 Yoshida et al. May 1988 A
4753651 Eckenhoff Jun 1988 A
4762791 Goeddel et al. Aug 1988 A
4765989 Wong et al. Aug 1988 A
4783337 Wong et al. Nov 1988 A
4820638 Swetly et al. Apr 1989 A
4826144 Balsells May 1989 A
4830344 Balsells May 1989 A
4845196 Cowling Jul 1989 A
4847079 Kwan Jul 1989 A
4851228 Zentner et al. Jul 1989 A
4865845 Eckenhoff et al. Sep 1989 A
4873080 Brickl et al. Oct 1989 A
4874388 Wong et al. Oct 1989 A
4876781 Balsells Oct 1989 A
4885166 Meyer et al. Dec 1989 A
4886668 Haslam et al. Dec 1989 A
4892778 Theeuwes et al. Jan 1990 A
4893795 Balsells Jan 1990 A
4897471 Stabinsky Jan 1990 A
4907788 Balsells Mar 1990 A
4915366 Balsells Apr 1990 A
4915949 Wong et al. Apr 1990 A
4915954 Ayer et al. Apr 1990 A
4917887 Hauptmann et al. Apr 1990 A
4917895 Lee et al. Apr 1990 A
4927687 Nuwayser May 1990 A
4929554 Goeddel et al. May 1990 A
4931285 Edgren et al. Jun 1990 A
4934666 Balsells Jun 1990 A
4940465 Theeuwes et al. Jul 1990 A
4952402 Sparks et al. Aug 1990 A
4961253 Balsells Oct 1990 A
4964204 Balsells Oct 1990 A
4969884 Yum Nov 1990 A
4974821 Balsells Dec 1990 A
4976966 Theeuwes et al. Dec 1990 A
5004689 Fiers et al. Apr 1991 A
5006346 Theeuwes et al. Apr 1991 A
5019382 Cummins, Jr. May 1991 A
5023088 Wong et al. Jun 1991 A
5024842 Edgren et al. Jun 1991 A
5030216 Theeuwes et al. Jul 1991 A
5034229 Magruder et al. Jul 1991 A
5057318 Magruder et al. Oct 1991 A
5059423 Magruder et al. Oct 1991 A
5071642 Lahr et al. Dec 1991 A
5072070 Balsells Dec 1991 A
5079388 Balsells Jan 1992 A
5091188 Haynes Feb 1992 A
5108078 Balsells Apr 1992 A
5110596 Magruder et al. May 1992 A
5112614 Magruder et al. May 1992 A
5113938 Clayton May 1992 A
5117066 Balsells May 1992 A
5118666 Habener Jun 1992 A
5120306 Gosselin Jun 1992 A
5120712 Habener Jun 1992 A
5120832 Goeddel et al. Jun 1992 A
5122128 Cardinal et al. Jun 1992 A
5126142 Ayer et al. Jun 1992 A
5134244 Balsells Jul 1992 A
5137727 Eckenhoff Aug 1992 A
5151093 Theeuwes et al. Sep 1992 A
5160122 Balsells Nov 1992 A
5160743 Edgren et al. Nov 1992 A
5161806 Balsells Nov 1992 A
5180591 Magruder et al. Jan 1993 A
5190765 Jao et al. Mar 1993 A
5203849 Balsells Apr 1993 A
5207752 Sorenson et al. May 1993 A
5209746 Balaban et al. May 1993 A
5213809 Wright et al. May 1993 A
5219572 Sivaramakrishnan Jun 1993 A
5221278 Linkwitz et al. Jun 1993 A
5223265 Wong Jun 1993 A
5231176 Goeddel et al. Jul 1993 A
5234424 Yum et al. Aug 1993 A
5234692 Magruder et al. Aug 1993 A
5234693 Magruder et al. Aug 1993 A
5234695 Hobbs et al. Aug 1993 A
5252338 Jao et al. Oct 1993 A
5260069 Chen Nov 1993 A
5278151 Korb et al. Jan 1994 A
5279608 Cherif Cheikh Jan 1994 A
5284655 Bogdansky et al. Feb 1994 A
5290271 Jernberg Mar 1994 A
5300302 Tachon et al. Apr 1994 A
5308348 Balaban et al. May 1994 A
5312389 Theeuwes et al. May 1994 A
5312390 Wong May 1994 A
5318558 Linkwitz et al. Jun 1994 A
5318780 Viegas et al. Jun 1994 A
5320616 Magruder et al. Jun 1994 A
5324280 Wong et al. Jun 1994 A
5336057 Fukuda et al. Aug 1994 A
5352662 Brooks et al. Oct 1994 A
5368588 Bettinger Nov 1994 A
5368863 Eckenhoff et al. Nov 1994 A
5371089 Rattan Dec 1994 A
5374620 Clark et al. Dec 1994 A
5385738 Yamahira et al. Jan 1995 A
5411951 Mitchell May 1995 A
5413572 Wong et al. May 1995 A
5413672 Hirotsuji et al. May 1995 A
5424286 Eng Jun 1995 A
5429602 Hauser Jul 1995 A
5443459 Wong et al. Aug 1995 A
5445829 Paradissis et al. Aug 1995 A
5456679 Balaban et al. Oct 1995 A
5458888 Chen Oct 1995 A
5464929 Bezwada et al. Nov 1995 A
5472708 Chen Dec 1995 A
5486365 Takado et al. Jan 1996 A
5498255 Wong et al. Mar 1996 A
5511355 Dingler Apr 1996 A
5512293 Landrau et al. Apr 1996 A
5512549 Chen et al. Apr 1996 A
5514110 Teh May 1996 A
5529914 Hubbell et al. Jun 1996 A
5531736 Wong et al. Jul 1996 A
5540665 Mercado et al. Jul 1996 A
5540912 Roorda et al. Jul 1996 A
5543156 Roorda et al. Aug 1996 A
5545618 Buckley et al. Aug 1996 A
5557318 Gabriel Sep 1996 A
5571525 Roorda et al. Nov 1996 A
5574008 Johnson et al. Nov 1996 A
5574137 Gray et al. Nov 1996 A
5580578 Oshlack et al. Dec 1996 A
5595751 Bezwada Jan 1997 A
5595759 Wright et al. Jan 1997 A
5597579 Bezwada et al. Jan 1997 A
5602010 Hauptmann et al. Feb 1997 A
5605688 Himmler et al. Feb 1997 A
5607687 Bezwada et al. Mar 1997 A
5609885 Rivera et al. Mar 1997 A
5614221 Fjellstrom Mar 1997 A
5614492 Habener Mar 1997 A
5618552 Bezwada et al. Apr 1997 A
5620698 Bezwada et al. Apr 1997 A
5620705 Dong et al. Apr 1997 A
5633011 Dong et al. May 1997 A
5635213 Nystrom et al. Jun 1997 A
5639477 Maruyama et al. Jun 1997 A
5645850 Bezwada et al. Jul 1997 A
5648088 Bezwada et al. Jul 1997 A
5660847 Magruder et al. Aug 1997 A
5660858 Parikh et al. Aug 1997 A
5660861 Jao et al. Aug 1997 A
5668170 Gyory Sep 1997 A
5676942 Testa et al. Oct 1997 A
5686097 Taskovich et al. Nov 1997 A
5690925 Gray et al. Nov 1997 A
5690952 Magruder et al. Nov 1997 A
5698213 Jamiolkowski et al. Dec 1997 A
5700486 Canal et al. Dec 1997 A
5700583 Jamiolkowski et al. Dec 1997 A
5703200 Bezwada et al. Dec 1997 A
5711967 Juch Jan 1998 A
5713847 Howard, III et al. Feb 1998 A
5728088 Magruder et al. Mar 1998 A
5728396 Peery et al. Mar 1998 A
5733572 Unger et al. Mar 1998 A
5736159 Chen et al. Apr 1998 A
5738845 Imakawa Apr 1998 A
5747058 Tipton et al. May 1998 A
5756450 Hahn et al. May 1998 A
5782396 Mastri et al. Jul 1998 A
5795591 Lee et al. Aug 1998 A
5795779 McCormick et al. Aug 1998 A
5807876 Armistead et al. Sep 1998 A
5814323 Lyle Sep 1998 A
5817129 Labrecque et al. Oct 1998 A
5830501 Dong et al. Nov 1998 A
5836935 Ashton et al. Nov 1998 A
5843891 Sherman Dec 1998 A
5844017 Jamiolkowski et al. Dec 1998 A
5858746 Hubbell et al. Jan 1999 A
5859150 Jamiolkowski et al. Jan 1999 A
5861166 Eckenhoff Jan 1999 A
5871770 Magruder et al. Feb 1999 A
5874388 Hsu Feb 1999 A
5876746 Jona et al. Mar 1999 A
5882676 Lee et al. Mar 1999 A
5904935 Eckenhoff et al. May 1999 A
5906816 Soos et al. May 1999 A
5906830 Farinas et al. May 1999 A
5908621 Glue et al. Jun 1999 A
5928666 Farinas et al. Jul 1999 A
5932547 Stevenson et al. Aug 1999 A
5938654 Wong et al. Aug 1999 A
5939286 Johnson et al. Aug 1999 A
5942223 Bazer et al. Aug 1999 A
5948430 Zerbe et al. Sep 1999 A
5958909 Habener Sep 1999 A
5962023 Jamiolkowski et al. Oct 1999 A
5972370 Eckenhoff et al. Oct 1999 A
5972373 Yajima et al. Oct 1999 A
5976109 Heruth Nov 1999 A
5985305 Peery et al. Nov 1999 A
5997527 Gumucio et al. Dec 1999 A
5997902 Maruyama et al. Dec 1999 A
6007805 Foster et al. Dec 1999 A
6017545 Modi Jan 2000 A
6022561 Carlsson et al. Feb 2000 A
6029361 Newman Feb 2000 A
6060450 Soos et al. May 2000 A
6069133 Carlo et al. May 2000 A
6074660 Jamiolkowski et al. Jun 2000 A
6074673 Guillen Jun 2000 A
6100346 Jamiolkowski et al. Aug 2000 A
6113938 Chen et al. Sep 2000 A
6124261 Stevenson et al. Sep 2000 A
6124281 Lewis et al. Sep 2000 A
6127520 Ueda et al. Oct 2000 A
6129761 Hubbell Oct 2000 A
6130200 Brodbeck et al. Oct 2000 A
6132420 Dionne et al. Oct 2000 A
6133249 Hills Oct 2000 A
6133429 Davis et al. Oct 2000 A
6147168 Jamiolkowski et al. Nov 2000 A
6156331 Peery et al. Dec 2000 A
6172046 Albrecht Jan 2001 B1
6174547 Dong et al. Jan 2001 B1
6177096 Zerbe et al. Jan 2001 B1
6183461 Matsuura et al. Feb 2001 B1
6187095 Labrecque et al. Feb 2001 B1
6190350 Davis et al. Feb 2001 B1
6191102 DiMarchi et al. Feb 2001 B1
6204022 Johnson et al. Mar 2001 B1
6217906 Gumucio et al. Apr 2001 B1
6217908 Mathiowitz et al. Apr 2001 B1
6218431 Schoen et al. Apr 2001 B1
6224894 Jamiolkowski et al. May 2001 B1
6235712 Stevenson et al. May 2001 B1
6245357 Edgren et al. Jun 2001 B1
6248112 Gambale et al. Jun 2001 B1
6251435 Jamiolkowski et al. Jun 2001 B1
6258377 New et al. Jul 2001 B1
6261584 Peery et al. Jul 2001 B1
6268343 Knudsen et al. Jul 2001 B1
6270787 Ayer Aug 2001 B1
6283949 Roorda Sep 2001 B1
6284264 Zerbe et al. Sep 2001 B1
6284725 Coolidge et al. Sep 2001 B1
6284727 Kim et al. Sep 2001 B1
6287295 Chen et al. Sep 2001 B1
6329336 Bridon et al. Dec 2001 B1
6331311 Brodbeck et al. Dec 2001 B1
6372218 Cummins, Jr. Apr 2002 B1
6372256 Jamiolkowski et al. Apr 2002 B2
6375978 Kleiner et al. Apr 2002 B1
6395292 Peery et al. May 2002 B2
6403655 Bezwada et al. Jun 2002 B1
6419952 Wong et al. Jul 2002 B2
6433144 Morris et al. Aug 2002 B1
6436091 Harper et al. Aug 2002 B1
6447522 Gambale et al. Sep 2002 B2
6451974 Hansen Sep 2002 B1
6458385 Jamiolkowski et al. Oct 2002 B2
6458924 Knudsen et al. Oct 2002 B2
6464688 Harper et al. Oct 2002 B1
6468961 Brodbeck et al. Oct 2002 B1
6471688 Harper et al. Oct 2002 B1
6472512 LaFleur et al. Oct 2002 B1
6485706 McCoy et al. Nov 2002 B1
6506724 Hiles et al. Jan 2003 B1
6508808 Carr et al. Jan 2003 B1
6514500 Bridon et al. Feb 2003 B1
6514517 Jamiolkowski et al. Feb 2003 B2
6524305 Peterson et al. Feb 2003 B1
6528486 Larsen et al. Mar 2003 B1
6541021 Johnson et al. Apr 2003 B1
6544252 Theeuwes et al. Apr 2003 B1
6551613 Dong et al. Apr 2003 B1
6569420 Chen et al. May 2003 B2
6572890 Faour et al. Jun 2003 B2
6579851 Goeke et al. Jun 2003 B2
6592887 Zerbe et al. Jul 2003 B2
6593295 Bridon et al. Jul 2003 B2
6635268 Peery et al. Oct 2003 B2
6670368 Breault et al. Dec 2003 B1
6673767 Brodbeck et al. Jan 2004 B1
6682522 Carr et al. Jan 2004 B2
6703225 Kojima et al. Mar 2004 B1
6703359 Young et al. Mar 2004 B1
6706689 Coolidge et al. Mar 2004 B2
6709671 Zerbe et al. Mar 2004 B2
6720407 Hughes et al. Apr 2004 B1
6730328 Maskiewicz et al. May 2004 B2
6767887 Hoffmann et al. Jul 2004 B1
6821949 Bridon et al. Nov 2004 B2
6833256 Pontzer et al. Dec 2004 B1
6835194 Johnson et al. Dec 2004 B2
6840931 Peterson et al. Jan 2005 B2
6849708 Habener Feb 2005 B1
6849714 Bridon et al. Feb 2005 B1
6858576 Young et al. Feb 2005 B1
6872700 Young et al. Mar 2005 B1
6875748 Manthorpe et al. Apr 2005 B2
6887470 Bridon et al. May 2005 B1
6887849 Bridon et al. May 2005 B2
6899887 Ayer May 2005 B2
6902744 Kolterman et al. Jun 2005 B1
6903186 Dong Jun 2005 B1
6923800 Chen et al. Aug 2005 B2
6924264 Prickett et al. Aug 2005 B1
6939556 Lautenbach Sep 2005 B2
6956026 Beeley et al. Oct 2005 B2
6969702 Bertilsson et al. Nov 2005 B2
6976981 Ayer Dec 2005 B2
6989366 Beeley et al. Jan 2006 B2
6992065 Okumu Jan 2006 B2
6997922 Theeuwes et al. Feb 2006 B2
7014636 Gilbert Mar 2006 B2
7022674 DeFelippis et al. Apr 2006 B2
7041646 Pan et al. May 2006 B2
7074423 Fereira et al. Jul 2006 B2
7084243 Glaesner et al. Aug 2006 B2
7101567 Sano et al. Sep 2006 B1
7101843 Glaesner et al. Sep 2006 B2
7112335 Lautenbach Sep 2006 B2
7115569 Beeley et al. Oct 2006 B2
7138375 Beeley et al. Nov 2006 B2
7138486 Habener et al. Nov 2006 B2
7141547 Rosen et al. Nov 2006 B2
7144863 DeFelippis et al. Dec 2006 B2
7153825 Young et al. Dec 2006 B2
7157555 Beeley et al. Jan 2007 B1
7163688 Peery et al. Jan 2007 B2
7199217 DiMarchi et al. Apr 2007 B2
7205409 Pei et al. Apr 2007 B2
7207982 Dionne et al. Apr 2007 B2
7241457 Chen et al. Jul 2007 B2
7258869 Berry et al. Aug 2007 B1
7297761 Beeley et al. Nov 2007 B2
7316680 Gilbert Jan 2008 B2
7393827 Nadler Jul 2008 B2
7407499 Trautman Aug 2008 B2
7442682 Kitaura et al. Oct 2008 B2
7456254 Wright et al. Nov 2008 B2
7459432 Cowley et al. Dec 2008 B2
7521423 Young et al. Apr 2009 B2
7563871 Wright et al. Jul 2009 B2
7612176 Wright et al. Nov 2009 B2
7655254 Dennis et al. Feb 2010 B2
7655257 Peery et al. Feb 2010 B2
7666835 Bloom et al. Feb 2010 B2
7682356 Alessi Mar 2010 B2
7727519 Moran Jun 2010 B2
7731947 Eliaz et al. Jun 2010 B2
7741269 Young et al. Jun 2010 B2
7825091 Bloom et al. Nov 2010 B2
7829109 Chen et al. Nov 2010 B2
7833543 Gibson et al. Nov 2010 B2
7879028 Alessi Feb 2011 B2
7919109 Berry et al. Apr 2011 B2
7959938 Rohloff et al. Jun 2011 B2
7964183 Eliaz et al. Jun 2011 B2
8048438 Berry et al. Nov 2011 B2
8052996 Lautenbach Nov 2011 B2
8058233 Cowley et al. Nov 2011 B2
8101576 Bloom Jan 2012 B2
8114430 Rohloff et al. Feb 2012 B2
8114437 Rohloff Feb 2012 B2
8158150 Lautenbach Apr 2012 B2
8173150 Berry et al. May 2012 B2
8206745 Rohloff Jun 2012 B2
8211467 Rohloff Jul 2012 B2
8217001 Cowley et al. Jul 2012 B2
8257691 Eliaz et al. Sep 2012 B2
8263545 Levy et al. Sep 2012 B2
8263736 Bloom Sep 2012 B2
8268341 Berry Sep 2012 B2
8273365 Lautenbach Sep 2012 B2
8273713 Pittner et al. Sep 2012 B2
8278267 Weyer et al. Oct 2012 B2
8298561 Alessi et al. Oct 2012 B2
8299025 Alessi et al. Oct 2012 B2
8343140 Alessi Jan 2013 B2
8367095 Lautenbach Feb 2013 B2
8372424 Berry et al. Feb 2013 B2
8398967 Eliaz et al. Mar 2013 B2
8440226 Rohloff et al. May 2013 B2
8460694 Rohloff et al. Jun 2013 B2
8470353 Lautenbach Jun 2013 B2
8801700 Alessi Aug 2014 B2
8865202 Zerbe et al. Oct 2014 B2
8926595 Alessi Jan 2015 B2
8940316 Alessi et al. Jan 2015 B2
8992961 Berry et al. Mar 2015 B2
8992962 Lautenbach Mar 2015 B2
9095553 Rohloff et al. Aug 2015 B2
20010012511 Bezwada et al. Aug 2001 A1
20010021377 Jamiolkowski et al. Sep 2001 A1
20010021822 Ayer Sep 2001 A1
20010022974 Ayer Sep 2001 A1
20010027311 Chen et al. Oct 2001 A1
20010036472 Wong et al. Nov 2001 A1
20010037190 Jung Nov 2001 A1
20020001631 Okumu Jan 2002 A1
20020004481 Cleland et al. Jan 2002 A1
20020012818 Ruppi et al. Jan 2002 A1
20020034532 Brodbeck et al. Mar 2002 A1
20020037309 Jaworowicz et al. Mar 2002 A1
20020048600 Bhatt et al. Apr 2002 A1
20020136848 Yoshii et al. Sep 2002 A1
20020137666 Beeley et al. Sep 2002 A1
20020141985 Pittner et al. Oct 2002 A1
20020197185 Jamiolkowski et al. Dec 2002 A1
20030032947 Harper et al. Feb 2003 A1
20030044467 Brodbeck et al. Mar 2003 A1
20030045454 Okumu et al. Mar 2003 A1
20030059376 Libbey, III et al. Mar 2003 A1
20030060425 Ahlem et al. Mar 2003 A1
20030104063 Babcock et al. Jun 2003 A1
20030108608 Laridon et al. Jun 2003 A1
20030108609 Berry et al. Jun 2003 A1
20030113380 Ramstack et al. Jun 2003 A1
20030118660 Rickey et al. Jun 2003 A1
20030138403 Drustrup Jul 2003 A1
20030138491 Tracy et al. Jul 2003 A1
20030157178 Chen et al. Aug 2003 A1
20030170289 Chen et al. Sep 2003 A1
20030180364 Chen et al. Sep 2003 A1
20030186858 Arentsen Oct 2003 A1
20030211974 Brodbeck et al. Nov 2003 A1
20030215515 Truong-Le et al. Nov 2003 A1
20040001689 Goldsmith et al. Jan 2004 A1
20040001889 Chen et al. Jan 2004 A1
20040002442 Pan et al. Jan 2004 A1
20040022859 Chen et al. Feb 2004 A1
20040024068 Levy et al. Feb 2004 A1
20040024069 Chen et al. Feb 2004 A1
20040029784 Hathaway Feb 2004 A1
20040039376 Peery et al. Feb 2004 A1
20040097906 Fereira et al. May 2004 A1
20040101557 Gibson et al. May 2004 A1
20040102762 Gilbert May 2004 A1
20040115236 Chan et al. Jun 2004 A1
20040142867 Oi et al. Jul 2004 A1
20040151753 Chen et al. Aug 2004 A1
20040157951 Wolf Aug 2004 A1
20040198654 Glaesner et al. Oct 2004 A1
20040209801 Brand et al. Oct 2004 A1
20040224903 Berry et al. Nov 2004 A1
20040225113 LaFleur et al. Nov 2004 A1
20040243106 Ayer Dec 2004 A1
20040265273 Li et al. Dec 2004 A1
20040266683 Hathaway et al. Dec 2004 A1
20040266692 Young et al. Dec 2004 A1
20050004557 Russell Jan 2005 A1
20050008661 Fereira et al. Jan 2005 A1
20050009742 Bertilsson et al. Jan 2005 A1
20050010196 Fereira et al. Jan 2005 A1
20050070883 Brown et al. Mar 2005 A1
20050079200 Rathenow et al. Apr 2005 A1
20050079202 Chen et al. Apr 2005 A1
20050095284 Trautman May 2005 A1
20050101943 Ayer et al. May 2005 A1
20050106214 Chen May 2005 A1
20050112188 Eliaz et al. May 2005 A1
20050118206 Luk et al. Jun 2005 A1
20050118221 Blakely et al. Jun 2005 A1
20050131386 Freeman et al. Jun 2005 A1
20050175701 Pan et al. Aug 2005 A1
20050201980 Moran Sep 2005 A1
20050215475 Ong et al. Sep 2005 A1
20050266087 Junnarkar et al. Dec 2005 A1
20050271702 Wright et al. Dec 2005 A1
20050276856 Fereira et al. Dec 2005 A1
20050281879 Chen et al. Dec 2005 A1
20060013879 Brodbeck et al. Jan 2006 A9
20060014678 Cowley et al. Jan 2006 A1
20060030526 Liu et al. Feb 2006 A1
20060069029 Kolterman et al. Mar 2006 A1
20060084604 Kitaura et al. Apr 2006 A1
20060094652 Levy et al. May 2006 A1
20060141040 Chen et al. Jun 2006 A1
20060142234 Chen et al. Jun 2006 A1
20060160736 Nadler Jul 2006 A1
20060178304 Juul-Mortensen et al. Aug 2006 A1
20060193918 Rohloff et al. Aug 2006 A1
20060216242 Rohloff et al. Sep 2006 A1
20060233841 Brodbeck et al. Oct 2006 A1
20060246138 Rohloff et al. Nov 2006 A1
20060251618 Dennis et al. Nov 2006 A1
20060263433 Ayer et al. Nov 2006 A1
20060264890 Moberg et al. Nov 2006 A1
20060280795 Penhasi et al. Dec 2006 A1
20060293232 Levy et al. Dec 2006 A1
20070027105 Junnarkar et al. Feb 2007 A1
20070166352 Wright et al. Jul 2007 A1
20070248572 Moran et al. Oct 2007 A1
20070281024 Lautenbach et al. Dec 2007 A1
20080038316 Wong et al. Feb 2008 A1
20080064636 Bloom et al. Mar 2008 A1
20080091176 Alessi et al. Apr 2008 A1
20080112994 Junnarkar et al. May 2008 A1
20080200383 Jennings et al. Aug 2008 A1
20080207512 Roth et al. Aug 2008 A1
20080226625 Berry et al. Sep 2008 A1
20080226689 Berry et al. Sep 2008 A1
20080260838 Hokenson et al. Oct 2008 A1
20080260840 Alessi et al. Oct 2008 A1
20080312157 Levy et al. Dec 2008 A1
20090022727 Houston et al. Jan 2009 A1
20090042781 Petersen et al. Feb 2009 A1
20090074734 Rottiers Mar 2009 A1
20090087408 Berry et al. Apr 2009 A1
20090156474 Roth et al. Jun 2009 A1
20090163447 Maggio Jun 2009 A1
20090186817 Ghosh et al. Jul 2009 A1
20090202481 Li et al. Aug 2009 A1
20090202608 Alessi et al. Aug 2009 A1
20090209460 Young et al. Aug 2009 A1
20090210019 Kim et al. Aug 2009 A1
20090215694 Kolterman et al. Aug 2009 A1
20090247463 Wright et al. Oct 2009 A1
20090286723 Levy et al. Nov 2009 A1
20090312246 Baron et al. Dec 2009 A1
20100092566 Alessi et al. Apr 2010 A1
20100105627 Salama et al. Apr 2010 A1
20100144621 Kim et al. Jun 2010 A1
20100185184 Alessi et al. Jul 2010 A1
20100297209 Rohloff et al. Nov 2010 A1
20110076317 Alessi et al. Mar 2011 A1
20110104111 Rohloff et al. May 2011 A1
20110152182 Alsina-Fernandez et al. Jun 2011 A1
20110160708 Berry et al. Jun 2011 A1
20110166554 Alessi et al. Jul 2011 A1
20110264077 Rohloff et al. Oct 2011 A1
20110306549 Tatarkiewicz et al. Dec 2011 A1
20120178687 Alessi et al. Jul 2012 A1
20120208755 Leung Aug 2012 A1
20130052237 Eliaz et al. Feb 2013 A1
20150111818 Alessi et al. Apr 2015 A1
20150231256 Berry et al. Aug 2015 A1
Foreign Referenced Citations (129)
Number Date Country
0079405 May 1983 EP
0254394 Jan 1988 EP
0295411 Dec 1988 EP
0368339 May 1990 EP
0373867 Jun 1990 EP
0431942 Jun 1991 EP
0379147 Sep 1994 EP
0627231 Dec 1994 EP
0729747 May 1997 EP
0771817 May 1997 EP
0841359 May 1998 EP
0767689 Jun 1999 EP
1046399 Oct 2000 EP
1084703 Mar 2001 EP
1600187 Jan 2009 EP
2020990 Sep 2010 EP
640907 Jul 1928 FR
1049104 Nov 1966 GB
1518683 Jul 1978 GB
9241153 Sep 1997 JP
11-100353 Apr 1999 JP
2006213727 Aug 2006 JP
592113 Aug 2012 NZ
200634060 Oct 2006 TW
WO 9107160 May 1991 WO
WO 9306819 Apr 1993 WO
WO 9306821 Apr 1993 WO
WO 9308832 May 1993 WO
WO 9309763 May 1993 WO
WO 9323083 Nov 1993 WO
WO 9409743 May 1994 WO
WO 9421262 Sep 1994 WO
WO 9501167 Jan 1995 WO
WO 9509006 Apr 1995 WO
WO 9509007 Apr 1995 WO
WO 9534285 Dec 1995 WO
WO 96001134 Jan 1996 WO
WO 9603116 Feb 1996 WO
WO 9639142 Dec 1996 WO
WO 9640049 Dec 1996 WO
WO 9640139 Dec 1996 WO
WO 9640355 Dec 1996 WO
WO 9715289 May 1997 WO
WO 9715296 May 1997 WO
WO 9728181 Aug 1997 WO
WO 9746204 Dec 1997 WO
WO 9747339 Dec 1997 WO
WO 9800152 Jan 1998 WO
WO 9800157 Jan 1998 WO
WO 9800158 Jan 1998 WO
WO 9802169 Jan 1998 WO
WO 9816250 Apr 1998 WO
WO 9817315 Apr 1998 WO
WO 9820930 May 1998 WO
WO 9827960 Jul 1998 WO
WO 9827962 Jul 1998 WO
WO 9827963 Jul 1998 WO
WO 9830231 Jul 1998 WO
WO 9832463 Jul 1998 WO
WO 9842317 Oct 1998 WO
WO 9847487 Oct 1998 WO
WO 9851282 Nov 1998 WO
WO 9903453 Jan 1999 WO
WO 9904767 Feb 1999 WO
WO 9904768 Feb 1999 WO
WO 9916419 Apr 1999 WO
WO 9925728 May 1999 WO
WO 9929306 Jun 1999 WO
WO 9933446 Jul 1999 WO
WO 9933449 Jul 1999 WO
WO 9939700 Aug 1999 WO
WO 9940788 Aug 1999 WO
WO 9944659 Sep 1999 WO
WO 9962501 Dec 1999 WO
WO 9964061 Dec 1999 WO
WO 0013663 Mar 2000 WO
WO 0029206 May 2000 WO
WO 0038652 Jul 2000 WO
WO 0039280 Jul 2000 WO
WO 0040273 Jul 2000 WO
WO 0041548 Jul 2000 WO
WO 0045790 Aug 2000 WO
WO 0054745 Sep 2000 WO
WO 0066138 Nov 2000 WO
WO 0143528 Jun 2001 WO
WO 0151041 Jul 2001 WO
WO 0178683 Oct 2001 WO
WO 0228366 Apr 2002 WO
WO 0236072 May 2002 WO
WO 0243800 Jun 2002 WO
WO 0245752 Jun 2002 WO
WO 0247716 Jun 2002 WO
WO 02067895 Sep 2002 WO
WO 02069983 Sep 2002 WO
WO 02076344 Oct 2002 WO
WO 02085428 Oct 2002 WO
WO 03000230 Jan 2003 WO
WO 03011892 Feb 2003 WO
WO 03024357 Mar 2003 WO
WO 03024503 Mar 2003 WO
WO 03030923 Apr 2003 WO
WO 03041684 May 2003 WO
WO 03072113 Sep 2003 WO
WO 03072133 Sep 2003 WO
WO 2004002565 Jan 2004 WO
WO 2004052336 Jun 2004 WO
WO 2004056338 Jul 2004 WO
WO 2004089335 Oct 2004 WO
WO 2005048930 Jun 2005 WO
WO 2005048952 Jun 2005 WO
WO 2005102293 Nov 2005 WO
WO 2006017772 Feb 2006 WO
WO 2006023526 Mar 2006 WO
WO 2006081279 Aug 2006 WO
WO 2006083761 Aug 2006 WO
WO 2006084139 Aug 2006 WO
WO 2006101815 Sep 2006 WO
WO 2006111169 Oct 2006 WO
WO 2007024700 Mar 2007 WO
WO 2007056681 May 2007 WO
WO 2007075534 Jul 2007 WO
WO 2007084460 Jul 2007 WO
WO 2007133778 Nov 2007 WO
WO 2007140416 Dec 2007 WO
WO 2008021133 Feb 2008 WO
WO 2008061355 May 2008 WO
WO 2008133908 Nov 2008 WO
WO 2008134425 Nov 2008 WO
WO 2009109927 Sep 2009 WO
Non-Patent Literature Citations (256)
Entry
International Search Report and Written Opinion for International Application No. PCT/US2004/010107, mailed Nov. 4, 2004.
International Preliminary Report on Patentability for International Application No. PCT/US2004/010107, dated Feb. 24, 2005.
International Search Report and Written Opinion for International Application No. PCT/US2004/010106, mailed Aug. 30, 2004.
International Preliminary Report on Patentability for International Application No. PCT/US2004/010106, dated Jul. 8, 2005.
Office Action for U.S. Appl. No. 11/347,562, mailed Feb. 4, 2010, 9 pages.
Office Action for U.S. Appl. No. 11/347,562, mailed Sep. 7, 2010, 20 pages.
International Search Report and Written Opinion for International Application No. PCT/US2006/003192, mailed Jul. 28, 2006.
International Preliminary Report on Patentability for International Application No. PCT/US2006/003192, dated Aug. 7, 2007.
Office Action for U.S. Appl. No. 12/827,265, mailed Mar. 30, 2011, 10 pages.
Office Action for U.S. Appl. No. 13/158,137, mailed Dec. 13, 2011, 13 pages.
Office Action for U.S. Appl. No. 13/526,375, mailed Sep. 14, 2012, 13 pages.
Office Action for U.S. Appl. No. 12/925,864, mailed Dec. 13, 2011, 11 pages.
Office Action for U.S. Appl. No. 13/647,228, mailed Jan. 2, 2013, 5 pages.
Office Action for U.S. Appl. No. 13/647,873, mailed Sep. 11, 2014, 7 pages.
Office Action for U.S. Appl. No. 13/647,873, mailed Jan. 3, 2013, 5 pages.
Office Action for U.S. Appl. No. 13/647,873, mailed Jun. 18, 2013, 5 pages.
Office Action for U.S. Appl. No. 11/755,494, mailed Dec. 27, 2010, 10 pages.
Office Action for U.S. Appl. No. 11/755,494, mailed Jun. 8, 2011, 15 pages.
International Search Report and Written Opinion for International Application No. PCT/US2007/069990, mailed Feb. 26, 2008.
International Preliminary Report on Patentability for International Application No. PCT/US2007/069990, dated Dec. 3, 2008.
Office Action for U.S. Appl. No. 13/433,287, mailed Jun. 19, 2012, 5 pages.
Office Action for U.S. Appl. No. 13/601,939, mailed Oct. 25, 2012, 5 pages.
Office Action for U.S. Appl. No. 13/740,187, mailed Apr. 11, 2013, 6 pages.
Office Action for U.S. Appl. No. 13/898,358, mailed Jul. 17, 2014, 6 pages.
Office Action for U.S. Appl. No. 13/209,328, mailed Feb. 16, 2012, 5 pages.
International Search Report and Written Opinion for International Application No. PCT/US2004/009755, mailed Nov. 22, 2004.
International Preliminary Report on Patentability for International Application No. PCT/US2004/009755, dated Jul. 8, 2005.
Office Action for U.S. Appl. No. 12/148,896, mailed Aug. 23, 2012, 6 pages.
Office Action for U.S. Appl. No. 12/148,896, mailed Oct. 20, 2009, 10 pages.
Office Action for U.S. Appl. No. 12/148,896, mailed May 14, 2010, 8 pages.
International Preliminary Report on Patentability for International Application No. PCT/US2008/005235, mailed Apr. 11, 2008.
International Search Report and Written Opinion for International Application No. PCT/US2008/005235, mailed Dec. 19, 2008.
Office Action for U.S. Appl. No. 12/927,432, mailed Mar. 26, 2014, 8 pages.
Bell, G. I. et al., “Hamster preproglucagon contains the sequence of glucagon and two related peptides,” Nature, 302:716-718 (1983).
Clark, J. B. et al., “The diabetic Zucker fatty rat,” Proc. Soc. Exp. Biol., Med., 173(1): 68-75 (1983).
Henry, R. R. et al., “Comparing ITCA 650, continuous subcutaneous delivery of exenatide via DUROS® device, vs. twice daily exenatide injections in metformin-treated type 2 diabetes,” ITCA 650 phase 2 oral presentation at the 46th Annual Meeting of the European Association for the Study of Diabetes in Stockholm, Sweden (Sep. 20-24, 2010).
Dash, A. K. et al., “Therapeutic applications of implantable drug delivery systems,” Journal of Pharmacological and Toxicological Methods, 40(1):1-12 (1998).
Deacon, C. F. et al., “GLP-1-(9-36) amide reduces blood glucose in anesthetized pigs by a mechanism that does not involve insulin secretion,” Am. J. Physiol. Endocrinol. Metab., 282:E873-E879 (2002).
Efendic, S. et al., et al., “Overview of incretin hormones,” Horm. Metab. Res., 36(11-12):742-746 (2004).
Eissele, R. et al., “Rat gastric somatostatin and gastrin release: interactions of exendin-4 and truncated glucagon-like peptide-1 (GLP-1) amide,” Life Sci., 55(8):629-634 (1994).
Eng, J. et al., “Purification and structure of exendin-3, a new pancreatic secretagogue isolated from Heloderma horridum venom,” J. Biol. Chem., 265(33):20259-20262 (1990).
Eng, J. et al., “Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas,” J. Biol. Chem., 267(11):7402-7405 (1992).
Ghiglione, M., et al., “How glucagon-like is glucagon-like peptide-1?” Diabetologia, 27:599-600 (1984).
Goke, R. et al., “Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells,” J. Biol. Chem., 268(26):19650-19655 (1993).
Gutniak, M. et al., “Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus,” N. Engl. J. Med., 326(20):1316-1322 (1992).
Heinrich, G. et al., “Pre-proglucagon messenger ribonucleic acid: nucleotide and encoded amino acid sequences of the rat pancreatic complementary deoxyribonucleic acid,” Endocrinol., 115:2176-2181 (1984).
Lopez, L. C. et al., “Mammalian pancreatic preproglucagon contains three glucagon-related peptides,” Proc. Natl. Acad. Sci. USA, 80(18):5485-5489 (1983).
Lund, P. K. et al., “Pancreatic preproglucagon cDNA contains two glucagon-related coding sequences arranged in tandem,” Proc. Natl. Acad. Sci. USA, 79(2):345-349 (1982).
Meier, J. J. et al., “The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans,” Am. J. Physiol. Endocrinol. Metab., 290(6):E1118-E1123 (2006).
Mojsov, S., “Structural requirements for biological activity of glucagon-like peptide-I,” Int. J. Peptide Protein Research, 40:333-343 (1992).
Nauck, M. A. et al., “Normalization of fasting glycaemia by intravenous GLP-1 ([7-36 amide] or [7-37]) in type 2 diabetic patients,” Diabet. Med., 15(11):937-945(1998).
Patzelt, C. et al., “Identification and processing of proglucagon in pancreatic islets,” Nature, 282:260-266 (1979).
Peterson, R. G. et al., “Zucker Diabetic Fatty Rat as a Model for Non-insulin-dependent Diabetes Mellitus,” ILAR Journal, 32(3):16-19 (1990).
Peterson, R. G. et al., “Neuropathic complications in the Zucker diabetic fatty rat (ZDF/Drt-fa),” Frontiers in diabetes research. Lessons from Animal Diabetes III, Shafrir, E. (ed.), pp. 456-458, Smith-Gordon, London (1990).
Pohl, M. et al., “Molecular cloning of the helodermin and exendin-4 cDNAs in the lizard. Relationship to vasoactive intestinal polypeptide/pituitary adenylate cyclase activating polypeptide and glucagon-like peptide 1 and evidence against the existence of mammalian homologues,” J. Biol. Chem., 273(16):9778-9784 (1998).
Press Release, Intarcia Therapeutics, Inc., “Intarcia Presents Positive ITCA 650 Phase 2 Study Results for Type 2 Diabetes at EASD,” (Sep. 22, 2010).
Press Release, “Intarcia Therapeutics Announces Final Results from a Phase 2 Study of Injectable Omega Interferon plus Ribavirin for the Treatment of Hepatits C Genotype-1 ,” NLV Partners Press Coverage Portofolio News (Apr. 12, 2007).
Schepp, W. et al., “Exendin-4 and exendin-(9-39)NH2: agonist and antagonist, respectively, at the rat parietal cell receptor for glucagon-like peptide-1-(7-36)NH2,” Eur. J. Pharmacol., 269(2):183-191 (1994).
Sparks, J. D. et al., “Lipoprotein alterations in 10- and 20-week-old Zucker diabetic fatty rats: hyperinsulinemic versus insulinopenic hyperglycemia,” Metabolism, 47(11):1315-1324 (1998).
Tseng, C. C. et al., “Glucose-dependent insulinotropic peptide: structure of the precursor and tissue-specific expression in rat,” PNAS USA, 90(5):1992-1996 (1993).
Vrabec, J. T., “Tympanic membrane perforations in the diabetic rat: a model of impaired wound healing,” Otolaryngol. Head Neck Surg., 118(3 Pt. 1):304-308 (1998).
Young, A. A. et al., “Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta),” Diabetes, 48(5):1026-1034 (1999).
Office Action for U.S. Appl. No. 14/605,348, mailed Dec. 4, 2015, 14 pages.
Office Action for U.S. Appl. No. 14/749,178, mailed Feb. 11, 2016, 9 pages.
First Office Action for Chinese Patent Application No. 201410262400.X, mailed Dec. 14, 2015, 14 pages.
“Abstracts 2007,” Diabetologia Clinical & Experimental Diabetes & Metabolism 50(1):S243, ¶ [0586] (Aug. 21, 2007) (XP002538652).
Jetschmann et al., “Open-label rising-dose study of omega interferon in IFN-naive patients with chronic hepatitis C,” Gastroenterology 122:A278-A347 (Apr. 1, 2002) (Abstract M1454).
Bray, “Gut Signals and Energy Balance: Ghrelin, Peptide YY, Leptin, and Amylin,” (slides and transcript for presentation at Medscape CME on Dec. 19, 2007).
“Implantable infusion pumps: technology poised for takeoff,” BBI Newsletter 17(12):209-211 (Dec. 1994).
Adamson et al., “Phase I trial and pharmacokinetic study of all-trans-retinoic acid administered on an intermittent schedule in combination with interferon-alpha2a in pediatric patients with refractory cancer,” J. Clin. Oncol. 15(11):3330-3337 (Nov. 1997).
Adolf et al., “Monoclonal antibodies and enzyme immunoassays specific for human interferon (IFN) ω1: evidence that IFN-ω1 is a component of human leukocyte IFN,” Virology 175(2):410-471 (Apr. 1990).
Adolf et al., “Antigenic structure of human interferon ω1 (Interferon αll1): comparison with other human interferons,” J. Gen. Virol. 68(6):1669-1676 (Jun. 1987).
Adolf et al., “Purification and characterization of natural human interferon ω1,” J. Bio. Chem. 265(16):9290-9295 (Jun. 1990).
Adolf et al., “Human interferon ω1: isolation of the gene, expression in Chinese hamster ovary cells and characterization of the recombinant protein,” Biochim. Biophys. Acta 108(9):167-174 (Jun. 1991).
Andrx Pharmaceuticals, LLC, ANDA for Concerta® Extended-Release Tablets, 6 pages (correspondence dated Sep. 6, 2005).
ASTM International, Annual Book of ASTM Standards, 8.02:208-211, 584-587 (1984).
Ansel et al., “Dosage Form Design: Pharmaceutical and Formulation Considerations,”Pharmaceutical Dosage Forms and Drug Delivery Systems, Ch. 3 at 87-92 (7th ed. Lippincott Williams & Wilkins 1999).
Ansel et al., “Modified-Release Dosage Forms and Drug Delivery Systems,”Pharmaceutical Dosage Forms and Drug Delivery Systems, Ch. 8 at 229-243 (7th ed. Lippincott Williams & Wilkins 1999).
Aulitzky, “Acute hematologic effects of interferon α, interferon γ, tumor necrosis factor α and Interleukin 2,” Ann. Hemetol. 62(1):25-31 (Feb. 1991).
Hauck, “Engineer's Guide to Plastics,” Materials Engineering 5(72):38-45 (Jul. 17, 1972).
Bailon et al., “Rational Design of a Potent, Long-lasting Form of Interferon: A 40 kDa Branched Polyethylene Glycol-conjugated Interferon Alpha-2a for the Treatment of Hepatitis C” Bioconjugate Chemistry 12(2):195-202 (2001).
Bakan et al., “Physicochemical Characterization of a Synthetic Lipid Emulsion for Hepatocyte-Selective Delivery of Lipophilic Compounds: Application to Polyiodinated triglycerides as Contrast Agents for Computed Tomography,” J. Pharm. Sci., 85(9):908-914 (1996).
Bakhtiar et al, “Taking Delivery,” Soap Perfumery & Cosmetics 76(3):59-65 (2003) (liposomes in cosmetic delivery systems).
Balkwill, “Interferons,” Lancet 1(8646):1060-1063 (May 1989).
Bauer et al., “Non-aqueous emulsions as vehicles for capsule fillings,” Drug Dev. & Industrial Pharmacy 10(5):699-712 (1984).
Bekkering et al., “Estimation of early hepatitis C viral clearance in patients receiving daily interferon and ribavirin therapy using a mathematical model,” Hepatology 33(2):419-423 (Feb. 2001).
Bell et al, “Impact of moisture on thermally induced denaturation and decomposition of lyophilized bovine somatotropin,” Drug Delivery Research & Dev. Biopolymers, (35):201-209 (1995).
Bell et al., “Hamster preproglucagon contains the sequence of glucagon and two related peptides,” Nature 302:716-718 (1983).
Bertoncello et al., “Haematopoietic radioprotection by Cremophor EL: a polyethoxylated castor oil,” Int. J. Radiat. Biol. 67(1):57-64 (1995).
Bohlinder et al., “Use and characteristics of a novel lipid particle-forming matrix as a drug-carrier system,” Euro. J. Pharm. Sci. 2(4):271-279 (1994).
Bolinger et al., “Recombinant interferon γ for treatment of chronic granulomatous disease and other disorders,” Clin. Pharm. 11(10):834-850 (Oct. 1992).
Bonkovsky et al., “Outcomes research in chronic viral hepatitis C: effects of interferon therapy,” Can. J. Gastroenterol. 14(Supp. B):21B-29B (Jul.-Aug. 2000).
Borden et al., “Second-generation interferons for cancer: clinical targets,” Semin. Cancer Biol. 10(2):125-144 (Apr. 2000).
Boue et al., “Antiviral and antiluteolytic activity of recombinant bovine IFN-ω1 obtained from Pichia pastoris,” J. Interferon & Cytokine Res. 20:677-683 (2000).
Buckwold et. al. “Antiviral activity of CHO-SS cell-derived human omega interferon and other human interferons against HCV RNA replicons and related viruses,” Antiviral Res. 73(2):118-25 (Feb. 2007) (Epub Sep. 11, 2006).
Cantor, “Theory of lipid monolayers comprised of mixtures of flexible and stiff amphiphiles in anthermal solvents: fluid phase coexistence,” J. Chem. Physics 104(20):8082-8095 (1996).
Cas No. 56-81-5 (Nov. 16, 1984).
Chang et al., “Biodegradeable polyester implants and suspension injection for sustained release of a cognitive enhancer,” Pharm. Tech. 20(1):80-84 (1996).
Chapman et al., “Physical Studies of Phospholipids. VI. Thermotropic and Lyotropic Mesomorphism of Some 1,2-Diacylphosphatidylcholines (lecithins),” Chem. & Physics of Lipids 1(5):445-475 (1967).
Chaumeil, “Micronization: a method of improving the bioavailability of poorly soluble drugs,” Methods & Findings in Experimental & Clinical Pharmacology 20(3):211-215 (1998).
Clark et al., “The diabetic Zucker fatty rat,” Proc. Soc. Exp. Biol. 173(1):68-75 (1983).
Condino-Neto, “Interferon-γ improves splicing efficiency of CYBB gene transcripts in an interferon responsive variant of chronic granulomatous disease due to a splice site consensus region mutation,” Blood 95(11):3548-3554 (Jun. 2000).
Darney, “Subdermal progestin implant contraception,” Current Opinion in Obstetrics & Gynecology 3:470-476 (1991).
Das et al., “Reviewing Antisense Oligonucleotide Therapy: Part 2, Delivery Issues,” BioPharm. 2(11):44-51 (1999).
Davis et al., “Durability of viral response to interferon alone or in combination with oral ribavirin in patients with chronic hepatitis C,” Prog. Abstr. 50th Annu. Mtg. Postgrad. Courses Am. Assn. Study Liver Dis., Dallas, TX, Abstract 570 (Nov. 5-9, 1999).
Desai et al., “Protein structure in the lyophilized state: a hydrogen isotope exchange/NMR study with bovine pancreatic trypsin inhibitor,” J. Am. Chem. Soc. 116(21):9420-9422 (1994).
Di Marco et al., “Combined treatment of relapse of chronic hepatitis C with high-dose α-2B interferon plus ribavirin for 6 or 12 months,” Prog. Abstr. 50th Annu. Mtg. Postgrad. Courses Am. Assn. Study Liver Dis., Dallas, TX, Abstract 569 (Nov. 5-9, 1999).
Dorr et al., “Phase I-II trial of interferon-alpha 2b by continuous subcutaneous infusion over 28 days,” J. Interferon Res. 8:717-725 (1988).
Uhlig et al., “The electro-smotic acutation of implantable insulin micropumps,” J. Biomed. Materials Res. 17:931-943 (1983).
Elias et al., “Infusional Interleukin-2 and 5-fluorouracil with subcutaneous interferon-α for the treatment of patients with advanced renal cell carcinoma: a southwest oncology group Phase II study,” Cancer 89(3):597-603 (Aug. 2000).
Eppstein et al., “Biological activity of liposome-encapsulated murine interferon γ is mediated by a cell membrane receptor,” PNAS USA 82:3688-3692 (1985).
Eros et al., “Multiple phase emulsions as controlled drug delivery therapeutic systems,” Proc.-Conf. Colloid Chem. 193-196 (1993).
Fang et al., “The impact of baseline liver histology on virologic response to interferon α-2b±ρ ribavirin therapy in patients with chronic hepatitis C,” Prog. Abstr. 50th Annu. Mtg. Postgrad. Courses Am. Assn. Study Liver Dis., Dallas, TX, Abstract 572 (Nov. 5-9, 1999).
Felker et al., “The Rate of Transfer of Unesterified Cholesterol from Rat Erythrocytes to Emulsions Modeling Nascent Triglyceride-Rich Lipoproteins and Chylomicrons Depends on the Degree of Fluidity of the Surface,” J. Nutritional Biochem. 4(1):630-634 (1993).
Ferenci et al, “Combination of interferon (IFN) induction therapy and ribavirin in chronic hepatitis C,” Prog. Abstr. Dig. Dis. Week 2000, San Diego, CA, Abstract 977 (May 21-24, 2000).
Fontaine et al., “Recovery from chronic hepatitis C in long-term responders to ribavirin plus interferon α,” Lancet 356(9223):41 (Jul. 2000).
Franchetti et al., “Furanfurin and Thiophenfurin: Two Novel TiazofurinAnalogues. Synthesis, Structure, Antitumor Activity, and Interactions with Inosine Monophosphate Dehydrogenase” J. Medicinal Chem. 38(19):3829-3837 (1995).
Fujii et al., “Effect of phosphatidylcholine on Skin Permeation of Indomethacin from gel prepared with Liquid Paraffin and Hydrogenated Phospholipid,” Int'l J. Pharmaceutics 222(1):57-64 (2001).
Fujii et al., “Enhancement of skin permeation of miconazole by phospholipid and dodecyl 2-(N, N-dimethylamino) propionate (Ddaip),” Int'l J. Pharmaceutics 234(12):121-128 (2002).
Luft et al., “Electro-osmotic valve for the controlled administration of drugs,” Med. & Biological Engineering & Computing 45-50 (Jan. 1978) (non-English with English abstract).
Gan to Kagaku Ryoho, “Phase II study of recombinant leukocyte α interferon (Ro22-8181) in malignant brain tumors,” Cancer & Chemotherapy 12(4):913-920 (Apr. 1985) (non-English with English abtract).
Gappa et al., “Juvenile laryngeal papillomatosis—a case report,” Pneumologie 45(11):936-938 (Nov. 1991) (X0009079028) (non-English with English abstract).
Gause et al., “Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer” J. Clin. Oncol. 14(8):2234-2241 (Aug. 1996).
Glue et al., “A dose-ranging study of Peg-intron and ribavirin in chronic hepatitis C—safety, efficacy, and virological rationale,” Prog. Abstr. 50th Annu. Mtg. Postgrad. Courses Am. Assn. Study Liver Dis., Dallas, TX, Abstract 571 (Nov. 5-9, 1999).
Gonzales et al., “Randomized controlled trial including an initial 4-week ‘induction’ period during one year of high-dose interferon α-2B treatment for chronic hepatitis C,” Prog. Abstr. Dig. Dis. Week 2000, San Diego, CA, Abstract 975 (May 21-24, 2000).
Gosland et al., “A phase I trial of 5-day continuous infusion cisplatin and interferon alpha,” Cancer Chemother. Pharmacol. 37(1-2):39-46 (1995).
Grant et al., “Combination therapy with interferon-α plus N-acetyl cystein for chronic hepatitis C: a placebo controlled double-blind multicentre study,” J. Med. Virol. 61(4):439-442 (Aug. 2000).
Hageman, “The Role of Moisture in Protein Stability, ” Drug Dev. & Ind. Pharm. 14(14):2047-2070 (1988).
Heathcote et al., “Peginterferon alfa-2a in Patients With Chronic Hepatitis C and Cirrhosis,” New England J. Med. 343(23):1673-1680 (2000).
Heim et al., “Intracellular signaling and antiviral effects of interferons,” Dig. Liver Dis. 32(3):257-263 (Apr. 2000).
Hellstrand et al., “Histamine and cytokine therapy,” Acta Oncol. 37(4):347-353 (1998).
Hellstrand et al., “Histamine and the response to IFN-α in chronic hepatitis C,” Interferon Cytokine Res. 18(1):21-22 (Jan. 1998).
Hellstrand et al., “Histamine in immunotherapy of advanced melanoma: a pilot study,” Cancer Immunol Immunother. 39(6):416-419 (Dec. 1994).
Hisatomi et al., “Toxicity of polyoxyethylene hydrogenated castor oil 60 (HCO-60) in experimental animals,” J. Toxicol. Sci., 18(3):1-9 (1993).
Hodoshima, N. et al., “Lipid nanoparticles for delivering antitumor drugs,” International Journal of Pharmaceutics, 146(1):81-92 (1997).
Hoffmann-La Roche Inc., Pegasys® (peginterferon alfa-2a), 15 pages (2002).
Horton et al., “Antitumor effects of interferon-omega: in vivo therapy of human tumor xenografts in nude mice,” Cancer Res 59(16):4064-4068 (Aug. 1999).
Hubel et al., “A phase I/II study of idarubicin, dexamethasone and interferon-alpha (1-Dexa) in patients with relapsed or refractory multiple myeloma” Leukemia 11(Suppl 5):547-551 (Dec. 1997).
Jacobelli et al., “A phase I study of recombinant interferon-alpha administered as a seven-day continuous venous infusion at circadian-rhythm modulated rate in patients with cancer” Am. J. Clin. Oncol. 18(1):27-31 (1995).
IFNB Multiple Sclerosis Study Group, “Interferonβ-1b is effective in relapsing-remitting multiple sclerosis,” Neurology 43(4):655-667 (Apr. 1993).
Intermune® Inc., Infergen® (Interferon alfacon-1), 5 pages (2002).
Introduction to Antibodies, http ://www.chemicon.com/resource/ANT101/a1.asp, 8 pages (retrieved May 2, 2007).
Isaacs et al., “Virus interference. I. The interferon,” Pro. R. Soc. Lond. B. Biol. Sci. 147:258-267 (1957).
Jain et al., “Controlled delivery of drugs from a novel injectable in situ formed biodegradable PLGA microsphere system,” J. Microencapsulation 17(3):343-362 (2000).
Jordan et al., “Guidelines for Antiemetic Treatment of Chemotherapy-Induced Nausea and Vomiting: Past, Present and Future Recommendations,” the Oncologist 12(9):1143-1150 (2007).
Kabalnov et al., “Macroemulsion type and stability of alkane-water-phospholipid systems,” Abstracts of Papers, Part 1, 210th ACS National Meeting, 0/8412-3222-9, American Chemical Society, Chicago, IL (Aug. 20-24, 1995) (Abstract only).
Kabalnov et al., “Phospholipids as Emulsion Stabilizers.2. Phase Behavior Versus Emulsion Stability,” Journal of Colloid and Interface Science 184(1):227-235 (1996).
Khalili et al., “Interferon and ribavirin versus interferon and amantadine in interferon nonresponders with chronic hepatitis C,” Am. J. Gastroenterol. 95(5):1284-1289 (May 2000).
Kildsig et al., “Theoretical Justification of Reciprocal Rate Plots in Studies of Water Vapor Transmission through Films,” J. Pharma. Sci. 29(11):1634-01637 (Nov. 17, 1970).
Kirkwood et al., “Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684,” J. Clin. Oncol. 14(1):7-17 (1996).
Kita et al., “Characterization of a polyethylene glycol conjugate of recombinant human interferon-γ,” Drug Des. Deliv. 6(3):157-0167 (Sep. 1990).
Knepp et al, “Identification of antioxidants for prevention of peroxide-mediated oxidation of recombinant human ciliary neurotrophic factor and recombinant human nerve growth factor,” J. Pharm. Sci. Tech. 50(3):163-171 (1996).
Knepp et al., “Stability of nonaqueous suspension formulations of plasma derived factor IX and recombinant human alpha interferon at elevated temperatures,” Pharma. Res. 15(7):1090-1095 (1998).
Knobler et al., “Systemic α-interferon therapy of multiple sclerosis,” Neurology 34(10):1273-1279 (Oct. 1984).
Kovacevic et al., “Treatment of chronic viral hepatitis B in secondary membranoproliferative glomerulonephritis using recombinant α-2 interferon,” Maksic Dj Vojnosanit. Pregl. 57(2):235-240 (Mar.-Apr. 2000) (non-English with English abstract).
Kracke et al., “Mx proteins in blood leukocytes for monitoring interferon β-1b therapy in patients with MS,” Neurology 54(1):193-199 (Jan. 2000).
Kronenberger et al., “Influence of interferon-α on CD82-expression in HCV-positive patients,” Prog. Abstr. Dig. Dis. Week 2000, San Diego, CA, Abstract 976 (May 21-24, 2000).
Krown et al., “Interferons and interferon inducers in cancer treatment,” Semin. Oncol. 13(2):207-217 (1986).
Kubes et al., “Cross-species antiviral and antiproliferative activity of human interferon-ω,” J. Interferon Res. 14:57-59 (1994).
Kunzi et al., “Role of interferon-stimulated gene ISG-15 in the interferon-ω-mediated inhibition of human immunodeficiency virus replication,” J. Interferon Cytokine Res. 16(11):919-927 (Nov. 1996).
Larsson, “Stability of emulsions formed by polar lipids,” Progress in the Chemistry of Fats and Other Lipids 16:163-0169 (1978).
Lee et al., “Dynamics of hepatitis C virus quasispecies turnover during interferon-A treatment,” Prog. Abstr. Dig. Dis. Week 2000, San Diego, CA, Abstract 974 (May 21-24, 2000).
Lee, “Therapy of hepatits C: interferon alfa-2A trials,” Hepatology 26: 89S-95S (Sep. 1997) (XP000981288).
Lukaszewski et al., “Pegylated α interferon is an effective treatment for virulent Venezuelan equine encephalitis virus and has profound effects on host immune response to infection,” J. Virol. 74(11):5006-5015 (Jun. 2000).
Lundberg, “A submicron lipid emulsion coated with amphipathic polyethylene glycol for parenteral administration of paclitaxel (Taxol),” J. Pharm. & Pharmacol. 49(1):16-21 (1997).
Magnuson et al. “Enhanced recovery of a secreted mammalian protein from suspension culture of genetically modified tobacco cells,” Protein Expression & Purification 7:220-228 (1996).
Malley et al., “Chronic Toxicity and Oncogenicity of N-Methylpyrrolidone (Nmp) in Rats and Mice by Dietary Administration,” Drug Chem Toxicol. 24(4):315-38 (Nov. 2001).
Manning et al, “Stability of protein pharmaceuticals,” Pharm. Res. 6(11):903-918 (1989).
Marincola et al., “Combination therapy with interferon alfa-2a and interleukin-2 for the treatment of metastatic cancer,” J. Clinical Oncol. 13(5):1110-1122 (1995) (XP009078965).
Massey, “Interaction of vitamin E with saturated phospholipid bilayers,” Biochem. & Biophys. Res. Comms. 106(3):842-847 (1982).
Mchutchison et al., “Interferon α-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C,” N. Engl. J. Med. 339(21):1485-1492 (Nov. 1998).
Mchutchison, et al., “Open-label phase 1B study of hepatitis C viral dynamics with omega interferon treatment,” Hepatology 34(4):A333 (Oct. 1, 2001) (X0004716177) (Abstract Only).
Merad et al., “Generation of monocyte-derived dendritic cells from patients with renal cell cancer: modulation of their functional properties after therapy with biological response modifiers (IFN-α plus IL-2 and IL-12),” J. Immunother. 23(3):369-378 (May-Jun. 2000).
Milella et al., “Neutralizing antibodies to recombinant α-interferon and response to therapy in chronic hepatitis C infection,” Liver 13(3):146-150 (Jun. 1993).
Mohler, “Primer on electrodeposited coatings,” Materials Engineering 5:38-45 (1972).
Morgan, “Structure and Moisture Permeability of Film-Forming Poloyers,” Ind. Eng. Chem. 45(10):2296-2306 (1953).
Motzer et al., “Phase I trial of 40-kd branched pegylated interferon alfa-2a for patients with advanced renal cell carcinoma,” J. Clinical Oncol. 19(5):1312-1319 (2001).
Neumann et al., “IIepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon-alpha Therapy,” Science 282:103-107 (Dec. 1998).
Nieforth et al., “Use of an indirect pharmacodynamic stimulation model of MX protein induction to compare in vivo activity of interferon-α-2a and a polyethylene glycol-modified derivative in healthy subjects,” Clin. Pharmacol. Ther. 59(6):636-646 (Jun. 1996).
Norden et al., “Physicochemical characterization of a drug-containing phospholipid-stabilized o / w emulsion for intravenous administration,” Eur. J. Pharm. Sci. 13(4):393-401 (2001).
Olaso et al., “Early prediction of lack of response to treatment with interferon and interferon plus ribavirin using biochemical and virological criteria in patients with chronic hepatitis C,” Esp. Quimioter. 12(3):220-228 (Sep. 1999) (non-English with English abstract).
Ortiz, A. et al., “A differential scanning calorimetry study of the interaction of α tocopherol with mixtures of phospholipids,” Biochim et Biophys Acta 898(2):214-222 (1987).
Panitch, “Interferons in multiple sclerosis,” Drugs 44(6):946-962 (Dec. 1992).
Pimstone et al., “High dose (780 MIU/52 weeks) interferon monotherapy is highly effective treatment for hepatitis C,” Prog. Abstr. Dig. Dis. Week 2000, San Diego, CA, Abstract 973 (May 21-24, 2000).
Plauth et al, “Open-label phase II study of omega interferon in previously untreated HCV infected patients,” Hepatology 34(4):A331 (Oct. 1, 2001) (X004716169) (Abstract Only).
Plauth et al, “Open-label study of omega interferon in previously untreated HCV-infected patients,” J. Hepatology 36(Supp. 1):125 (Apr. 2002) (X0002511882) (Abstract Only).
Poynard et al., “Is an ‘a la carte’ combined interferon α 2b plus ribavirin possible for the first line treatment in patients with chronic hepatitis C,” Hepatology 31(1):211- 218 (Jan. 2000).
Poynard et al., “Randomized trial of interferon α 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α 2b plus placebo for 48 weeks for the treatment of chronic infection with hepatitis C virus,” Lancet 352(9138):1426-1432 (Oct. 1998).
Quesada et al., Interferons in Hematological Malignancies at 487-495 (eds. Baron et al., U. Tex. 1987).
Quintanar-Guerrero et al., “Applications of the ion-pair concept to hydrophilic substances with special emphasis on peptides,” Pharm. Res. 14(2):119-127 (1997).
Rajkuiviar et al., “Phase I evaluation of radiation combined with recombinant interferon alpha-2a and BCNU for patients with high-grade glioma,” Int'l J. Radiat. Oncol. Biol. Phys. 40(2):297-302 (Jan. 15, 1998).
Roche Pharmaceuticals, Roferon® -A (Interferon alfa-2a, recombinant), 22 pages (2003).
Roff et al., “Handbook of Common Polymers,” 72 pages (Cleveland Rubber Co. 1971).
Rogers et al., “Permeability Valves,” Ind. & Eng. Chem. 49(11):1933-1936 (Nov. 17, 1957).
Roman et al., “Cholestasis in the rat by means of intravenous administration of cyclosporine vehicle, Cremophor EL,” Transplantation 48(4);554-558 (1989).
Roth et al., “High Dose Etretinate and Interferon-alpha—A Phase I Study in Squamous Cell Carcinomas and Transitional Cell Carcinomas,” Acta Oncol. 38(5):613-617 (1999).
Roth et al., “Combination therapy with amylin and peptide YY[3-36] in obese rodents: anorexigenic synergy and weight loss additivity,” Endocrinol. 148(12):605461 (Dec. 2007).
Schering Corp., Intron® A for Injection, 6 pages (2001).
Schering Corp., PEG-Intron™ (Peginterferon alfa-2b) Powder for Injection, 29 pages (2003).
Schmalfub, et al., “Modification of drug penetration into human skin using microemulsions,” J. Controlled Release 46(3):279-285 (1997).
Sen et al., “The interferon system: a bird's eye view of its biochemistry,” J. Biol. Chem. 267(8):5017-5020 (Mar. 1992).
Shiffman et al., “A decline in HCV-RNA level during interferon or ihterferon/ribavirin therapy in patients with virologic nonresponse is associated with an improvement in hepatic histology,” Prog. Abstr. 50th Annu. Mtg. Postgrad. Courses Am. Assn. Study Liver Dis., Dallas, TX, Abstract 567 (Nov. 5-9, 1999).
Shima et al., “Serum total bile acid level as a sensitive indicator of hepatic histological improvement in chronic hepatitis C patients responding to interferon treatment,” J. Gastroenterol. Hepatol. 15(3):294-299 (Mar. 2000).
Shiratori et al., “Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy,” Ann. Int. Med. 132(7):517-524 (Apr. 2000).
Simon et al., “A longitudinal study of T1 hypointense lesions in relapsing MS:MSCRG trial of interferon β1a,” Neurology 55(2):185-192 (Jul. 2000).
Sulkowski et al., “Pegylated Interferon Alfa-2A (Pegasys™ ) and Ribavirin Combination Therapy for Chronic Hepatitis C: A Phase II Open-Label Study” Gastroenterology 118(4, Supp. 2), Abstract 236 (2000).
Sulkowski et al., “Peginterferon-α-2a (40kD) and ribavirin in patients with chronic hepatitis C: a phase II open label study,” Biodrugs 16(2):105-109 (2002).
Talpaz et al., “Phase I study of polyethylene glycol formulation of interferon alpha-2B (Schering 54031) in Philadelphia chromosome-positive chronic myelogenous leukemia,” Blood 98(6):1708-1713 (2001).
Talsania et al., “Peripheral exendin-4 and peptide YY(3-36) synergistically reduce food intake through different mechanisms in mice,” Endocrinology 146(9):3748-56 (Sep. 2005).
Tanaka et al., “Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients,” Int. J. Cancer 87(5):741-749 (Sep. 2000).
Tong et al., “Prediction of response during interferon α 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison,” Hepatology 26(6):1640-01645 (Dec. 1997).
Touza Rey et al., “The clinical response to interferon-γ in a patient with chronic granulomatous disease and brain abscesses due to Aspergillus fumigatus,” Ann. Med. Int. 17(2):86-87 (Feb. 2000).
Trudeau et al., “A phase I study of recombinant human interferon alpha-2b combined with 5-fluorouracil and cisplatin in patients with advanced cancer” Cancer Chemother. Pharmacol. 35(6):496-500 (1995).
Tsung et al., “Preparation and Stabilization of Heparin/Gelatin Complex Coacervate Microcapsules,” J. Pharm. Sci. 86(5):603-7 (May 1997).
Unniappan et al., “Effects of dipeptidyl peptidase IV on the satiety actions of peptide YY,” Diabetologia; Clinical and Experimental Diabetes and Metabolism 49(8):1915-1923 (Jun. 27, 2006).
Vokes et al., “A phase I trial of concomitant chemoradiotherapy with cisplatin dose intensification and granulocyte-colony stimulating factor support for advanced malignancies of the chest,” Cancer Chemother. Pharmacol. 35(4):304-312 (1995).
Wang et al., “Preferential interaction of α-tocopherol with phosphatidylcholines in mixed aqueous dispersions of phosphatidylcholine and phosphatidylethanolamine,” Eur. J. Biochem. 267(21):6362-6368 (2000).
Wang et al., “Ripple phases induced by α-tocopherol in saturated diacylphosphatidylcholines,” Archives of Biochem. & Biophys. 377(2):304-314 (2000).
Wang et al., “The distribution of α-tocopherol in mixed aqueous dispersions of phosphatidylcholine and phosphattidylethanolamine,” Biochimica et Biophysica Acta-Biomembranes 1509(1-2):361-372 (2000).
Wang et al, “Parenteral formulations of proteins and peptides: stability and stabilizers,” J. Parenter. Sci. Technol. 42(2S):S4-S26 (1988).
Weinstock-Guttman et al., “What is new in the treatment of multiple sclerosis?” Drugs 59(3):401-410 (Mar. 2000).
Weissmann et al., “The interferon genes,” Prog. Nucleic Acid Res. Mol. Biol. 33:251-300 (1986).
Wright et al., “Preliminary experience with α-2b-interferon therapy of viral hepatitis in liver allograft recipients,” Transplantation 53(1):121-123 (Jan. 1992).
Young et al., “Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta),” Diabetes, 48(5):1026-1034 (1999).
Younossi et al., “The role of amantadine, rimantadine, ursodeoxycholic acid, and NSAIDs, alone or in combination with α interferons, in the treatment of chronic hepatitis C,” Semin. Liver Dis. 19(Supp. 1):95-102 (1999).
Yu et al., “Preparation, characterization, and in vivo evaluation of an oil suspension of a bovine growth hormone releasing factor analog,” J. Pharm. Sci. 85(4):396-401 (1996).
Zeidner et al., “Treatment of FeLV-induced immunodeficiency syndrome (feLV-FAIDS) with controlled release capsular implantation of 2′,3′-dideoxycytidine,” Antivir. Res. 11(3):147-160 (Apr. 1989).
Zein, “Interferons in the management of viral hepatitis,” Cytokines Cell Mol. Ther. 4(4):229-241 (Dec. 1998).
Zeuzem et al., “Peginterferon Alfa-2a in Patients with Chronic Hepatitis C,” New Engl. J. Med. 343(23):1666-1672 (2000).
Zeuzem et al., “Hepatitis C virus dynamics in vivo: effect of ribavirin and interferon α on viral turnover,” Hepatology 28(1):245-252 (Jul. 1998).
Zhang et al., “Report on Large Dosage Interferon to Treat 30 Cases of Viral Encephalitis,” J. Clinical Pediatrics 14(2):83-84 (1996).
Zhang et al, “A new strategy for enhancing the stability of lyophilized protein: the effect of the reconstitution medium on keratinocyte growth factor,” Pharm. Res. 12(10):1447-1452 (1995).
Zheng et al. “Therapeutic Effect of Interferon Varied Dose in Treating Virus Encephalitis,” Beijing Med. J. 13(2):80-81 (1998).
Ziesche et al., “A preliminary study of long-term treatment with interferon γ-lb and low-dose prednisolone in patients with idiopathic pulmonary fibrosis,” New Engl. J. Med. 341(17):1264-1269 (Oct. 1999).
Adolf, “Human interferon omega-a review,” Mult. Sclr. 1:S44-47 (1995).
Costantino et al., “Protein Spray Freeze Drying. 2. Effect of Formulation Variables on particle Size and Stability,” J. Pharm. Sci. 91:388-395 (2002).
Henry et al., “Comparing ITCA 650, continuous subcutaneous delivery of exenatide via DUROS® device, vs. twice daily exenatide injections in metformin-treated type 2 diabetes,” 21 pages (oral presentation at the 46th Annual Meeting of the European Association for the Study of Diabetes in Stockholm, Sweden, Sep. 20-24, 2010).
Huggins et al., “Synergistic antiviral effects of ribavirin and the C-nucleoside analogs tiazofurin and selenazofurin against togaviruses, bunyaviruses, and arenaviruses,” Antimicrobial Agents & Chemotherapy, 26(4):476-480 (1984).
Ishiwata et al., “Clinical effects of the recombinant feline interferon-omega on experimental parvovirus infection in beagle dogs,” J. Vet. Med. Sci. 60(8):911-917 (1998).
Johnson et al., “How interferons fight disease,” Sci. Am. 270(5):68-75 (May 1994).
Lublin et al., “Defining the clinical course of multiple sclerosis: results of an internatinal survey,” Neurology. 46:907-911 (1996).
Madsbad, “Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics)—preclinical and clinical results,” Best Practice & Research Clinical Endocrinology & Metabolism 23:463-77 (2009).
Nielsen, “Incretin mimetics and DPP-IV inhibitors for the treatment of type 2 diabetes,” Drug Discovery Today 10(10):703-710 (May 15, 2005).
Palmeri et al., “5-Fluorouracil and recombinant α-interferon-2a in the treatment of advanced colorectal carcinoma: a dose optimization study,” J. Chemotherapy 2(5):327-330 (Oct. 1990).
Patti et al., “Natural interferon-b treatment of relapsing-remitting and secondary-progressive multiple sclerosis patients: two-year study,” Acta. Neurol. Scand. 100:283-289 (1990).
Paty et al., “Interferon beta-1 b is effective in relapsing-remitting multple sclerosis,” Neurology 43:662-667 (1993).
PCT International Search Report for PCT/US2009/000916, 4 pages (Aug. 12, 2009).
Quianzon et al., “Lixisenatide-Once-daily Glucagon-like Peptide-1 Diabetes,” US Endocrinology 7(2):104-109 (2011).
Ratner et al., “Dose-dependent effects of the one-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metfmmin: a randomized, double-blind, placebo-controlled trial,” Diabetic Medicine 27(9):1024-1032 (Sep. 2010).
Roberts et al., “The Evolution of the Type I Interferonsl,” J. Interferon Cytokine Res. 18(10):805-816 (Oct. 1998).
Rohloff et al., “Duros Technology Delivers Peptides and Proteins at Consistent Rate Continuously for 3 to 12 Months,” J. Diabetes Sci. & Tech., 2(3):461-467 (May 1, 2008).
Sequence Listings for International Patent Application Publication No. W02009109927, WIPO Patentscope, 1 page (last visited Nov. 14, 2012), available at http://patentscope.wipo.int/search/docservicepdf—pct!id00000008776887.
Shire et al., “Challenges in the Development of High Protein Concentration Formulations,” J. Pharm. Sci. 93:1390-1402 (2004).
Smith, “Peripheral Neuro-hormones as a Strategy to Treat Obesity,” pages 1-35 (oral presentation at the 2007 Cardiometabolic Health Congress in Boston, MA, Sep. 26-29, 2007).
Written Opinion for International Patent Application No. PCT/US2009/005629 (Apr. 15, 2011) (corresponding to U.S. Appl. No. 12/587,946).
Zhang et al., “Efficacy observations of different dosages of interferon to treat 150 Hepatitis B carriers,” Current Physician 2(12):45-46 (1997).
Related Publications (1)
Number Date Country
20150231062 A1 Aug 2015 US
Provisional Applications (2)
Number Date Country
60809451 May 2006 US
60650225 Feb 2005 US
Divisions (1)
Number Date Country
Parent 11755494 May 2007 US
Child 13209328 US
Continuations (5)
Number Date Country
Parent 13898358 May 2013 US
Child 14632700 US
Parent 13740187 Jan 2013 US
Child 13898358 US
Parent 13601939 Aug 2012 US
Child 13740187 US
Parent 13433287 Mar 2012 US
Child 13601939 US
Parent 13209328 Aug 2011 US
Child 13433287 US
Continuation in Parts (1)
Number Date Country
Parent 11347562 Feb 2006 US
Child 11755494 US